Unnamed: 0,title,date,stock,sentiment
1331892.0,VIVUS Option Alert: Jul 17 $2 Calls Sweep (11) near the Ask: 1500 @ $0.221 vs 199 OI; Earnings 8/4 After Close [est] Ref=$1.13,2020-06-08 12:33:00-04:00,VVUS,positive
1331893.0,VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.,2020-06-02 07:34:00-04:00,VVUS,positive
1331894.0,"Vivus Shares Ticking Higher After Report That Australian Government Granted Patent For ""Methods of preventing progression to type 2 diabetes mellitus""",2020-05-27 12:44:00-04:00,VVUS,positive
1331895.0,"VIVUS Q1 EPS $(0.490) Beats $(0.800) Estimate, Sales $19.631M Beat $17.700M Estimate",2020-05-06 16:37:00-04:00,VVUS,neutral
1331896.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,VVUS,positive
1331897.0,Shares of several healthcare companies are trading lower on market weakness as investor uncertainty grows following quarterly earnings results from multiple companies.,2020-05-01 09:30:00-04:00,VVUS,negative
1331898.0,"Vivus Says on April 29, Entered Into Agreement With Trustee and Holder of About $170M of Co's Outstanding 4.50% Convertible Senior Notes Due May 1, 2020;  Noteholder Agreed to Grant to Co Grace Period With Respect to Payment of Principal Amount of Convertible Notes Payable to Noteholder on May 1",2020-05-01 08:39:00-04:00,VVUS,positive
1331899.0,VIVUS Reports Deal With IEH Biopharma To Grant 30-Day Grace Period To Restructure Corporate Debt,2020-05-01 08:35:00-04:00,VVUS,positive
1331900.0,VitalTech Partners With VIVUS Pharmaceuticals To Accelerate Launch Of Telehealth And Remote Patient Monitoring Module,2020-04-03 08:01:00-04:00,VVUS,neutral
1331901.0,72 Biggest Movers From Yesterday,2020-04-02 04:23:00-04:00,VVUS,neutral
1331902.0,Mid-Afternoon Market Update: Dow Tumbles 800 Points; Chembio Diagnostics Shares Spike Higher,2020-04-01 14:31:00-04:00,VVUS,positive
1331903.0,Why Vivus Is Trading Lower Today,2020-04-01 13:18:00-04:00,VVUS,negative
1331904.0,54 Stocks Moving In Wednesday's Mid-Day Session,2020-04-01 12:30:00-04:00,VVUS,neutral
1331905.0,Mid-Day Market Update: ProPetro Slides After Q4 Results; InflaRx Shares Jump,2020-04-01 12:11:00-04:00,VVUS,positive
1331906.0,Vivus shares are trading lower after the company priced its ~7.22 Million share common stock offering at $1.60 per share.,2020-04-01 10:45:00-04:00,VVUS,positive
1331907.0,Mid-Morning Market Update: Markets Open Lower; UniFirstTops Q2 Estimates,2020-04-01 10:26:00-04:00,VVUS,negative
1331908.0,VIVUS 13G Filing From Sabby Mgmt. Shows 9.97% Stake,2020-04-01 09:33:00-04:00,VVUS,neutral
1331909.0,VIVUS Prices ~7.22M Share Common Stock Offering At $1.60/Share,2020-04-01 09:05:00-04:00,VVUS,positive
1331910.0,20 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-04-01 07:45:00-04:00,VVUS,neutral
1331911.0,31 Stocks Moving in Wednesday's Pre-Market Session,2020-04-01 07:18:00-04:00,VVUS,neutral
1331912.0,Vivus Shares Rally On Accelerated Telemedicine Launch,2020-03-31 11:23:00-04:00,VVUS,positive
1331913.0,VIVUS Accelerates Launch Of Telemedicine And Remote Monitoring Modules,2020-03-31 07:31:00-04:00,VVUS,neutral
1331914.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,VVUS,neutral
1331915.0,Stocks That Hit 52-Week Lows On Wednesday,2020-03-18 11:37:00-04:00,VVUS,negative
1331916.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,VVUS,negative
1331917.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,VVUS,negative
1331918.0,Stocks That Hit 52-Week Lows On Wednesday,2020-03-11 11:41:00-04:00,VVUS,negative
1331919.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,VVUS,negative
1331921.0,92 Biggest Movers From Yesterday,2020-03-05 04:41:00-05:00,VVUS,neutral
1331922.0,60 Stocks Moving In Wednesday's Mid-Day Session,2020-03-04 12:11:00-05:00,VVUS,neutral
1331923.0,"Wells Fargo Maintains Equal-Weight on VIVUS, Lowers Price Target to $1.75",2020-03-04 08:06:00-05:00,VVUS,positive
1331924.0,"The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies",2020-03-04 07:37:00-05:00,VVUS,negative
1331925.0,38 Stocks Moving in Wednesday's Pre-Market Session,2020-03-04 07:18:00-05:00,VVUS,neutral
1331926.0,10 Stocks Moving In Tuesday's After-Hours Session,2020-03-03 16:47:00-05:00,VVUS,neutral
1331927.0,VIVUS shares are trading higher after the company reported better-than-expected Q4 EPS results.,2020-03-03 16:28:00-05:00,VVUS,positive
1331928.0,"VIVUS Q4 EPS $(0.61) Beats $(0.68) Estimate, Sales $17.254M Miss $19.14M Estimate",2020-03-03 16:10:00-05:00,VVUS,negative
1331929.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,VVUS,positive
1331930.0,VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia in Adolescents,2020-03-02 07:31:00-05:00,VVUS,positive
1331931.0,"The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off",2020-02-29 14:52:00-05:00,VVUS,neutral
1331932.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,VVUS,negative
1331933.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,VVUS,neutral
1331934.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,VVUS,negative
1331935.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,VVUS,positive
1331936.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-02-19 08:10:00-05:00,VVUS,neutral
1331937.0,VIVUS Announces Commercial Launch Of Qsymia In The Republic Of Korea Establishing New Royalty Revenue Stream,2020-02-19 07:32:00-05:00,VVUS,neutral
1331938.0,90 Biggest Movers From Yesterday,2020-02-06 05:15:00-05:00,VVUS,neutral
1331939.0,Mid-Afternoon Market Update: Greenhill Rises After Q4 Results; PC Connection Shares Slide,2020-02-05 14:32:00-05:00,VVUS,positive
1331940.0,68 Stocks Moving In Wednesday's Mid-Day Session,2020-02-05 12:16:00-05:00,VVUS,neutral
1331941.0,Mid-Day Market Update: Crude Oil Up 3.5%; Plantronics Shares Plummet,2020-02-05 12:02:00-05:00,VVUS,negative
1331942.0,Mid-Morning Market Update: Markets Open Higher; General Motors Posts Mixed Q4 Results,2020-02-05 10:12:00-05:00,VVUS,neutral
1331943.0,VIVUS Receives FDA Approval For Improved Formulation Of PANCREAZE With A 36-Month Shelf Life,2020-02-05 07:31:00-05:00,VVUS,positive
1331944.0,VIVUS Shares Spike ~13% Over Last Few Mins.; Not Seeing News To Justify Price Action,2020-02-03 14:27:00-05:00,VVUS,positive
1331946.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,VVUS,positive
1331947.0,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",2020-01-29 08:30:00-05:00,VVUS,neutral
1331948.0,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics",2020-01-28 07:12:00-05:00,VVUS,positive
1331949.0,20 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-01-07 07:53:00-05:00,VVUS,neutral
1331950.0,VIVUS Highlights Publication Of Data On Qsymia As A Weight Management Tool,2020-01-07 07:34:00-05:00,VVUS,neutral
1331951.0,VIVUS Reports Adoption Of Shareholder Rights Plan,2019-12-31 07:31:00-05:00,VVUS,neutral
1331952.0,30 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-12-18 08:11:00-05:00,VVUS,neutral
1331953.0,VIVUS Highlights Publication Of New Data For Qsymia In Adolescents With Obesity,2019-12-18 07:32:00-05:00,VVUS,neutral
1331954.0,VIVUS Announces New Clinical Data Demonstrating Qsymia Effectiveness In Reducing Binge Eating In Bulimia Nervosa PAtients,2019-11-20 07:32:00-05:00,VVUS,neutral
1331955.0,"VIVUS Q3 EPS $(1.04) Misses $(0.74) Estimate, Sales $17.97M Miss $20.01M Estimate",2019-11-05 16:18:00-05:00,VVUS,negative
1331956.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,VVUS,negative
1331957.0,VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe,2019-10-07 07:35:00-04:00,VVUS,positive
1331958.0,"VIVUS Reports Pres Ken Suh, COO Scott Oehrlein To Leave; Replacements Not Mentioned",2019-10-03 07:43:00-04:00,VVUS,negative
1331959.0,VIVUS Reports Initiation Of Pay Down Of $48.6M Secured Debt For Total Interest Savings Of $10.5M,2019-10-03 07:43:00-04:00,VVUS,positive
1331960.0,23 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-08-29 08:40:00-04:00,VVUS,neutral
1331961.0,60 Biggest Movers From Friday,2019-08-26 05:08:00-04:00,VVUS,neutral
1331962.0,"A Look At Benzinga Pro's Most-Searched Tickers For August 21, 2019",2019-08-21 12:15:00-04:00,VVUS,neutral
1331963.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday., August 21, 2019",2019-08-21 09:48:00-04:00,VVUS,positive
1331964.0,55 Biggest Movers From Yesterday,2019-08-21 05:07:00-04:00,VVUS,neutral
1331965.0,44 Stocks Moving In Tuesday's Mid-Day Session,2019-08-20 12:21:00-04:00,VVUS,neutral
1331966.0,22 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-08-20 08:32:00-04:00,VVUS,neutral
1331967.0,VIVUS Highlights Study Results Showing The ADdition Of Co.'s Qsymia To Gastric Sleeve Surgery Significantly Improves Weight Loss Compared with Surgery Alone,2019-08-20 07:33:00-04:00,VVUS,negative
1331968.0,"VIVUS Q2 EPS $(0.56) Beats $(0.99) Estimate, Sales $18.39M Beat $16.59M Estimate",2019-08-06 17:11:00-04:00,VVUS,neutral
1331969.0,VIVUS And Nordmark Amend Contract Manufacturing Agreement To Supply Current And Future Demand For PANCREAZE,2019-06-26 16:08:00-04:00,VVUS,positive
1331970.0,VIVUS Launches W-Medicine Platform To Enable Patients With Qsymia Prescriptions To Purchase The Medication Online,2019-06-11 07:32:00-04:00,VVUS,neutral
1331971.0,"FDA Reviewed Homepage Of Qsymia Caps For Oral Use Submitted By VIVUS, Says Qsymia Website Makes False, Misleading Claims And/Or Representations About Efficacy Of, Risks Associated With Drug",2019-05-30 09:06:00-04:00,VVUS,negative
1331972.0,VIVUS Initiates Phase Four Safety and Efficacy Study Of Qsymia In Obese Adolescents,2019-05-28 07:32:00-04:00,VVUS,positive
1331973.0,VIVUS 8-K Highlights Partnership With HarborPath Direct To Facilitate Access To PANCREAZE For Patients Without Health Insurance,2019-05-15 07:44:00-04:00,VVUS,neutral
1331974.0,"VIVUS Shares Spike ~1.5% Over Last Few Mins On Volume As Traders Circulate Word Of New Buy Rating, $10 Price Target By Zack's Small-Cap Research; BZ NOTE: Zack's Research Doesn't Normally Move Stocks",2019-05-02 14:12:00-04:00,VVUS,positive
1331975.0,"Vivus Q1 EPS $(0.75) Beats $(1.17) Estimate, Sales $16.15M Miss $16.2M Estimate",2019-04-30 17:12:00-04:00,VVUS,negative
1331976.0,VIVUS shares are trading higher after traders circulated documents showing the company won a contract award from the Department of Veterans National Acquisition Center.,2019-04-17 13:33:00-04:00,VVUS,positive
1331977.0,VIVUS Shares Spike ~6% As Traders Circulate FedBizOpps.gov Contract Award Doc From Dept. Of Veterans Affairs National Acquisition Center,2019-04-17 11:05:00-04:00,VVUS,positive
1331978.0,VIVUS Reports Marketing Approval Of Avanafil In Russian Federation For Treatment Of Erectile Dysfunction,2019-03-14 07:40:00-04:00,VVUS,positive
1331979.0,"Vivus Q4 EPS $(0.42) Beats $(0.53) Estimate, Sales $20.114M Beat $17M Estimate",2019-02-26 16:48:00-05:00,VVUS,neutral
1331980.0,56 Biggest Movers From Yesterday,2019-01-15 04:57:00-05:00,VVUS,neutral
1331981.0,41 Stocks Moving In Monday's Mid-Day Session,2019-01-14 13:04:00-05:00,VVUS,neutral
1331982.0,28 Stocks Moving In Monday's Pre-Market Session,2019-01-14 08:23:00-05:00,VVUS,neutral
1331983.0,"Stocks Which Set New 52-Week Low Today, Wed., Jan. 2, 2019",2019-01-02 13:08:00-05:00,VVUS,negative
1331984.0,"The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO",2018-12-28 07:29:00-05:00,VVUS,neutral
1331985.0,"The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede",2018-12-27 07:51:00-05:00,VVUS,neutral
1331986.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-12-13 08:02:00-05:00,VVUS,neutral
1331987.0,"The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen",2018-12-13 07:56:00-05:00,VVUS,positive
1331988.0,"UPDATE: VIVUS, Sanofi Chimie Have Extended Term Of Commercial Supply Deal For Avanafil From Dec. 31, 2018 To Dec. 31, 2023",2018-12-12 16:13:00-05:00,VVUS,neutral
1331989.0,"VIVUS 8-K Shows Amendment To Commercial Supply Deal With Sanofi Chimie: Sanofi Chimie Will Manufacture, Supply API For Co.'s Avanafil On Exclusive Basis In All Countries Where Co. Has Right To Sell Drug",2018-12-12 16:12:00-05:00,VVUS,positive
1331990.0,48 Biggest Movers From Friday,2018-12-10 05:23:00-05:00,VVUS,neutral
1331991.0,Seeing Sharp Spike In VIVUS Shares; Now Up 26%,2018-12-07 11:49:00-05:00,VVUS,positive
1331992.0,"Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018",2018-11-28 11:54:00-05:00,VVUS,negative
1331993.0,"The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings",2018-11-28 07:46:00-05:00,VVUS,neutral
1331994.0,48 Biggest Movers From Yesterday,2018-11-28 05:00:00-05:00,VVUS,neutral
1331995.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-11-27 12:25:00-05:00,VVUS,neutral
1331996.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018",2018-11-27 11:26:00-05:00,VVUS,negative
1331997.0,"The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial",2018-11-27 07:32:00-05:00,VVUS,negative
1331998.0,"Stocks Which Set New 52-Week Low The Prior Trading Session, Fri., Nov. 23, 2018",2018-11-26 10:44:00-05:00,VVUS,negative
1331999.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018",2018-11-20 09:12:00-05:00,VVUS,negative
1332000.0,"The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings",2018-11-20 08:29:00-05:00,VVUS,negative
1332001.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,VVUS,positive
1332002.0,74 Biggest Movers From Friday,2018-11-05 04:36:00-05:00,VVUS,neutral
1332003.0,"VIVUS, Inc. Q3 EPS $(0.87) Down From $(0.06) YoY, Sales $18.088M Up From $15.193M YoY",2018-11-01 17:46:00-04:00,VVUS,neutral
1332004.0,VIVUS Regains Compliance With Nasdaq Listing Requirements,2018-09-26 07:31:00-04:00,VVUS,neutral
1332005.0,60 Biggest Movers From Yesterday,2018-09-19 05:08:00-04:00,VVUS,neutral
1332006.0,48 Biggest Movers From Yesterday,2018-09-13 05:01:00-04:00,VVUS,neutral
1332007.0,38 Stocks Moving In Wednesday's Mid-Day Session,2018-09-12 12:28:00-04:00,VVUS,neutral
1332008.0,"VIVUS Halted On Circuit Breaker, Shares Are Up 24.47% At $6.41/Share",2018-09-12 10:07:00-04:00,VVUS,positive
1332009.0,48 Biggest Movers From Yesterday,2018-09-12 05:20:00-04:00,VVUS,neutral
1332010.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-09-11 12:31:00-04:00,VVUS,neutral
1332011.0,VIVUS Inc Shares Halted On Circuit Breaker; Up 11.9%,2018-09-11 09:49:00-04:00,VVUS,positive
1332012.0,"VIVUS Announces 1-For-10 Reverse Stock Split, Effective September 11",2018-09-10 07:30:00-04:00,VVUS,positive
1332013.0,"Vivus Q2 EPS $(0.12) Misses $(0.11) Estimate, Sales $14.96M Miss $16M Estimate",2018-08-07 17:18:00-04:00,VVUS,negative
1332014.0,41 Biggest Movers From Yesterday,2018-07-11 04:38:00-04:00,VVUS,neutral
1332015.0,32 Stocks Moving In Tuesday's Mid-Day Session,2018-07-10 12:20:00-04:00,VVUS,neutral
1332016.0,Vivus Shares Up 18% Premarket After Co. Announced Positive Preliminary Results From Phase 1 Trial Of VI-0106 For Pulmonary Arterial Hypertension,2018-07-10 08:55:00-04:00,VVUS,positive
1332017.0,VIVUS Announces Results From Phase 1 Clinical Trial Of VI-0106 In Pulmonary Arterial Hypertension,2018-07-10 07:31:00-04:00,VVUS,neutral
1332018.0,Benzinga Pro's 5 Stocks To Watch Today,2018-06-11 09:32:00-04:00,VVUS,neutral
1332019.0,"VIVUS Reports Has Met Closing Conditions For Purchase Of US, Canadian Rights To PANCREAZE Capsules For Treatment Of EPI From J&J's Janssen Pharma For $135M",2018-06-11 07:34:00-04:00,VVUS,neutral
1332020.0,"Roundup Of Biotech Stocks Up On No Positive Catalyst; Dare Bioscience Inc Up 23.2%, ATyr Pharma Up 17.7%, AzurRx BioPharma Up 16.8%, VIVUS Up 8.9%, Innovate Biopharmaceuticals Up 7.7%, IBio Up 6.5%, Evogene Up 6.0%",2018-06-08 10:36:00-04:00,VVUS,positive
1332021.0,Form 4 Filing Late Tuesday Showed Vivus Director Herm Rosenman Bought 50K Shares at Avg. Price of $0.77,2018-06-06 14:01:00-04:00,VVUS,positive
1332022.0,"Vivus Director Herm Rosenman Buys 50,000 @ Avg Price: $0.79",2018-05-31 16:41:00-04:00,VVUS,neutral
1332023.0,"Benzinga's Biggest Movers For The Week Of May 14, 2018",2018-05-18 16:00:00-04:00,VVUS,neutral
1332024.0,"VIVUS Shares Up 23.2% After Co. Earlier Received Letter Letter From Nasdaq Regarding Continued Listing; Co. Must Have Effected Reverse Stock Split, Evidenced Closing Bid Over $1/Share On Or Before Oct. 1, '18",2018-05-18 13:33:00-04:00,VVUS,positive
1332025.0,"VIVUS 8-K Shows Co. Received Letter From Nasdaq Informing Co. Hearings Panel Granted Request For Continued Listing Subject To Condition That On Or Before Oct. 1, '18, Co. Must Have Effected Reverse Stock Split, Evidenced Closing Bid Over $1/Share",2018-05-18 06:06:00-04:00,VVUS,positive
1332026.0,"VIVUS Shares Up 4.1% After Hours As CEO CEO John P Amos Buys 540,000 @ Avg Price: $0.56",2018-05-17 17:08:00-04:00,VVUS,positive
1332027.0,"Vivus CEO John P Amos Buys 540,000 @ Avg Price: $0.56",2018-05-17 17:06:00-04:00,VVUS,neutral
1332028.0,"UPDATE: FDA Offers Guidelines, Background For Reference Listed Drug Access Inquiries, Related To Claim Of Blocking Generic Rivals",2018-05-17 12:38:00-04:00,VVUS,negative
1332029.0,"FDA Commissioner Scot Gottlieb Highlights List Of Cos. Which Have Potentially Blocked Access To Samples Of Their Branded Products: Pfizer, Biogen, INSYS, VIVUS, Valeant, Corcept Therapeutics",2018-05-17 09:57:00-04:00,VVUS,negative
1332030.0,Form 4 Filing Late Tuesday Showed Vivus CEO John Amos Bought 540K Shares at $0.51 to $0.52,2018-05-16 13:25:00-04:00,VVUS,positive
1332031.0,"Vivus Q1 EPS $(0.10) Beats $(0.11) Estimate, Sales $11.9M Miss $16M Estimate",2018-05-08 16:29:00-04:00,VVUS,negative
1332032.0,"VIVUS Shares Up 50.7% After Co. Monday Named New CEO and COO, Tuesday Acquired PANCREAZE From Jannsen For $135M",2018-05-01 12:49:00-04:00,VVUS,positive
1332033.0,VIVUS Restructures Debt and Gains Access to New Capital,2018-05-01 07:24:00-04:00,VVUS,neutral
1332034.0,VIVUS Expands its Commercial Product Portfolio with the Acquisition of PANCREAZE From Janssen For $135M,2018-05-01 07:22:00-04:00,VVUS,positive
1332035.0,VIVUS Acquires PANCREAZE from Jannsen for $135M,2018-05-01 07:11:00-04:00,VVUS,neutral
1332036.0,"Vivus Names John Amos CEO, Scott Oehrlein COO",2018-04-30 16:29:00-04:00,VVUS,neutral
1332037.0,"VIVUS Reports Q4 EPS $(0.10) vs $(0.13) Est., Sales $11.941M vs $17M Est.",2018-03-13 16:06:00-04:00,VVUS,neutral
1332038.0,Orexigen Struggles As Contrave Commercialization Costs Rise,2018-01-05 10:54:00-05:00,VVUS,negative
1332039.0,"5 Stocks To Watch For December 27, 2017",2017-12-27 04:41:00-05:00,VVUS,neutral
1332040.0,UPDATE: VIVUS Says Board Is Working With Exec. Search Firm To Help Identify Permanent Replacement At CEO,2017-12-26 16:06:00-05:00,VVUS,positive
1332041.0,VIVUS Announces CEO Seth Fischer To STep Down; Thomas King Named Interim Replacement,2017-12-26 16:05:00-05:00,VVUS,neutral
1332042.0,"Vivus Reports Q3 EPS $(0.06) vs. $(0.13) Est., Sales $15.193M vs. $16M Est.",2017-11-07 16:11:00-05:00,VVUS,neutral
1332043.0,VIVUS Completes Tacrolimus Pre-IND Meeting With FDA,2017-11-02 10:04:00-04:00,VVUS,neutral
1332044.0,VIVUS Reports Racrolimus Received Orphan Drug Designation In EU For Treatment Of Pulmonary Arterial Hypertension,2017-09-06 16:13:00-04:00,VVUS,neutral
1332045.0,VIVUS and Alvogen Announce Marketing Agreement for Qsymia in the Republic of Korea,2017-09-05 08:03:00-04:00,VVUS,positive
1332046.0,"VIVUS Reports Seeltement With Dr. Reddy's Laboratories On Qsymia Patent Litigation, Dr. Reddy' Will Be Permitted To Sell A Generic Version Starting June 1, 2025",2017-08-30 16:08:00-04:00,VVUS,negative
1332047.0,EC Public Health Site Shows Orphan Medicinal Products Registry For VIVUS's Tacrolimus For Treatment Of Pulmonary Arterial Hypertension,2017-08-30 12:36:00-04:00,VVUS,neutral
1332048.0,"VIVUS Reports Q2 EPS $(0.13), Inline, Sales $11.227M vs $15M Est.",2017-08-03 16:23:00-04:00,VVUS,neutral
1332049.0,VIVUS Reports Settlement Of Qsymia Patent Litigation With Actavis,2017-07-05 16:15:00-04:00,VVUS,negative
1332096.0,"VIVUS Reports Q1 EPS $(0.01) vs $(0.14) Est., Sales $17.62M vs $13M Est.",2017-05-03 18:06:00-04:00,VVUS,neutral
1332097.0,"VIVUS, Inc. Reacquires STENDRA Commercial Rights from Sanofi, Terms Not Disclosed",2017-03-27 08:31:00-04:00,VVUS,neutral
1332098.0,15 Biggest Mid-Day Gainers For Thursday,2017-03-09 12:32:00-05:00,VVUS,neutral
1332099.0,Mid-Morning Market Update: Markets Edge Higher; Staples Earnings Miss Views,2017-03-09 09:58:00-05:00,VVUS,negative
1332100.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-03-09 08:29:00-05:00,VVUS,neutral
1332101.0,"VIVUS Reports Q4 EPS $0.54 vs. YoY $(0.12), Sales $81.80M vs. YoY $15.34M",2017-03-08 16:14:00-05:00,VVUS,neutral
1332102.0,VIVUS Enters Settlement Agreement With Hetero USA In Response To Hetero ANDA,2017-01-09 16:13:00-05:00,VVUS,positive
1332103.0,VIVUS Acquires Development Rights To Selten's Tacrolimus And Ascomycin For Pulmonary Arterial Hypertension,2017-01-09 09:01:00-05:00,VVUS,neutral
1332104.0,"VIVUS Reports Q3 EPS $(0.09) vs. Est. $(0.19), Rev. $13.35M vs. Est. $25.87M",2016-11-09 16:57:00-05:00,VVUS,neutral
1332105.0,"VIVUS, Metuchen Pharma Report License Deal for Commercial Rights to STENDRA",2016-10-03 08:31:00-04:00,VVUS,neutral
1332106.0,"VIVUS Extends Return Date Of STENDRA Commercial Rights To September 30, 2016",2016-08-29 16:32:00-04:00,VVUS,positive
1332107.0,"VIVUS Reports Q2 EPS $(0.11) vs $(0.48) in Same Qtr. Last Year, Sales $13.776M",2016-08-04 17:36:00-04:00,VVUS,neutral
1332108.0,VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents,2016-07-27 16:58:00-04:00,VVUS,negative
1332109.0,VIVUS Announces Favorable Markman Ruling in Qsymia(R) Patent Litigation,2016-07-21 18:18:00-04:00,VVUS,positive
1332110.0,Watch These 7 Huge Call Purchases In Friday Trade,2016-07-01 02:46:00-04:00,VVUS,positive
1332111.0,"VIVUS to Extend Return Date of STRENDA Commercial Rights Through August 31, 2016",2016-06-30 16:16:00-04:00,VVUS,positive
1332112.0,Option Alert: VVUS Aug16 2.0 Calls Sweep: 500 @  ASK  $0.04: 1000 traded vs 150 OI:  Earnings 8/4  $1.13 Ref,2016-06-30 13:19:00-04:00,VVUS,positive
1332113.0,VIVUS Received Notice From Hetero USA That It Has Filed An ANDA For Generic Versions Of All Strengths Of STENDRA Tablets To The FDA,2016-06-21 16:12:00-04:00,VVUS,positive
1332114.0,"UPDATE: Shares Of Vivus Spiking, Trading $1.25, Up ~10%",2016-06-14 15:47:00-04:00,VVUS,positive
1332115.0,UPDATE: Meg Tirrell Tweet Links to NBC News Article 'Which Diet Drug Works Best? It May Depend on You' Published Several Mins Ago,2016-06-14 15:44:00-04:00,VVUS,positive
1332116.0,Vivus Spikes to High (Now Up 8.6%) Following Tweet from Meg Tirrell Related to Qsymia,2016-06-14 15:44:00-04:00,VVUS,neutral
1332117.0,CNBC's Meg Tirrell Tweets '$VVUS's Qsymia tops weight loss drug study',2016-06-14 15:44:00-04:00,VVUS,positive
1332118.0,"North Tide Capital Buys 	2,160 Shares of Vivus  @ $1.4017/Share -Form 4",2016-04-05 16:13:00-04:00,VVUS,positive
1332119.0,"North Tide Capital LLC Buys 202,000 Shares of Vivus @$1.12/Share",2016-03-28 16:49:00-04:00,VVUS,positive
1332120.0,"VIVUS Reports Q4 EPS $(0.12), Inline, Sales $15.343M vs $22.9M Est.",2016-03-09 16:15:00-05:00,VVUS,neutral
1332121.0,"Earnings Scheduled For March 9, 2016",2016-03-09 04:07:00-05:00,VVUS,neutral
1332122.0,"Vivus And Oreixigen Have Too Many Problems For Investors, RBC's Simeonidis Claims",2016-02-29 10:08:00-05:00,VVUS,negative
1332123.0,RBC Capital Downgrades Vivus to Sector Perform,2016-02-29 07:57:00-05:00,VVUS,neutral
1332124.0,"VIVUS Reports Intent to Repurchase US, CAnadian Rights for Stendra, No Terms Disclosed",2015-12-31 13:01:00-05:00,VVUS,negative
1332125.0,Endo International Notifies Vivus It Will End Its Commercial Supply And License Agreements Related To Avanafil,2015-12-31 08:32:00-05:00,VVUS,positive
1332126.0,"8-K from Endo Int'l Shows Unit Auxilium Pharma, Endo Ventures, Provided Written Notice to VIVUS Related to Termination of License, Commercialization Deal",2015-12-30 16:39:00-05:00,VVUS,neutral
1332127.0,Hearing Unconfirmed Market Chatter in Vivus Regarding Icahn,2015-12-01 09:54:00-05:00,VVUS,negative
1332128.0,"VIVUS Reports Q3 EPS $(0.15) vs. Est. $(0.17), Rev. $24.936M vs. Est. $20.24M",2015-11-04 16:15:00-05:00,VVUS,neutral
1332129.0,Morning Market Gainers,2015-10-08 09:43:00-04:00,VVUS,neutral
1332130.0,VVUS +22% Premarket as Icahn Enterprises Announces Expiration of Tender Offer for Outstanding 4.50% Convertible Senior Notes Due 2020,2015-10-08 09:09:00-04:00,VVUS,positive
1332131.0,"Icahn Enterprises L.P. Reports Expiration of Tender Offer for Any and All of the Outstanding 4.50% Convertible Senior Notes Due 2020 of VIVUS, Inc.",2015-10-08 08:45:00-04:00,VVUS,positive
1332132.0,Vivus 8-K Filing Shows Co Appointed Johann Noor Mohamed As Interim CFO and Chief Accounting Officer,2015-10-05 16:10:00-04:00,VVUS,neutral
1332133.0,"VIVUS Board Reports Expression of No Opinion, Remains Neutral Related to Carl Icahn's Bid for Convertible Senior Notes",2015-09-22 16:06:00-04:00,VVUS,negative
1332134.0,Biotechs Coming Off One Of The Busiest Weeks In Recent Memory,2015-09-14 13:44:00-04:00,VVUS,neutral
1332135.0,Vivus Spikes Higher After-Hours,2015-09-10 16:29:00-04:00,VVUS,neutral
1332136.0,Option Alert: $VVUS Jan $2 Call; 1531 Contracts @Ask @$0.15; Now $1.38,2015-09-09 09:43:00-04:00,VVUS,positive
1332137.0,"Icahn Enterprises L.P. Reports Tender Offer for Any and All of the Outstanding 4.50% Convertible Senior Notes Due 2020 of VIVUS, Inc.",2015-09-09 09:04:00-04:00,VVUS,positive
1332138.0,"Option Alert: $VVUS Jan $2 Call Sweep; 1117 Contracts @Ask @$0.16, Now $1.31",2015-09-03 11:52:00-04:00,VVUS,positive
1332139.0,Mid-Day Market Update: Tuesday's Top Shorted Stocks,2015-08-18 14:28:00-04:00,VVUS,positive
1332140.0,Stocks Hitting 52-Week Lows,2015-07-31 10:23:00-04:00,VVUS,negative
1332141.0,Morning Market Losers,2015-07-31 10:00:00-04:00,VVUS,negative
1332142.0,"VIVUS Reports Q2 Loss $0.48 Vs Est Loss $0.24, Sales $23M Vs Est $18.76M",2015-07-30 16:12:00-04:00,VVUS,negative
1332143.0,Stocks Hitting 52-Week Lows,2015-07-08 10:17:00-04:00,VVUS,negative
1332144.0,Benzinga's Top #PreMarket Gainers,2015-07-06 08:17:00-04:00,VVUS,positive
1332145.0,"VIVUS reports Q1 EPS Loss $0.15 Vs Est Loss $0.22, Sales $32.2M Vs Est $21.76M",2015-05-05 16:00:00-04:00,VVUS,negative
1332146.0,"Earnings Scheduled For May 5, 2015",2015-05-05 04:27:00-04:00,VVUS,neutral
1332147.0,VIVUS Reports New Discount Program for Qsymia Through Sam's Club,2015-04-28 07:07:00-04:00,VVUS,neutral
1332148.0,VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia,2015-04-21 16:44:00-04:00,VVUS,neutral
1332149.0,"VIVUS Offers Operational Update, Including Key Decisions, Plans Related to Qsymia Caps",2015-03-30 16:06:00-04:00,VVUS,neutral
1332150.0,"Ferrellgas, Prothena Lead Friday's After-Hours Movers",2015-03-20 17:29:00-04:00,VVUS,neutral
1332151.0,Hearing EMEA in Process to Approve Qsymia in EU,2015-03-16 13:36:00-04:00,VVUS,neutral
1332152.0,8-K from VIVUS Shows Co. Received Notice from Teva Pharma of Filing with US FDA for ANDA for Generic Versions of All Strengths of Qsymia Capsules CIV,2015-03-10 07:13:00-04:00,VVUS,positive
1332153.0,"Vivus Says on March 4, Co Filed Lawsuit In U.S. District Court for District of NJ vs Actavis, Based on Actavis' Submission Of aNDA Which Infringes Intellectual Property Rights Relating to Qsymia",2015-03-09 07:11:00-04:00,VVUS,positive
1332154.0,JPM Securities Picks Through Biotech News For Winners,2015-02-25 12:41:00-05:00,VVUS,positive
1332155.0,"Wednesday's #PreMarket Movers: Hewlett-Packard, Dreamworks Animation Trending Lower",2015-02-25 09:22:00-05:00,VVUS,negative
1332156.0,UPDATE: VIVUS Posts Q4 Loss,2015-02-24 17:21:00-05:00,VVUS,negative
1332157.0,"Vivus Reports Q4 EPS $(0.25), Rev. $21.7M",2015-02-24 16:09:00-05:00,VVUS,neutral
1332158.0,"Earnings Scheduled For February 24, 2015",2015-02-24 04:57:00-05:00,VVUS,neutral
1332159.0,VIVUS Announces European Approval of SPEDRA Label Amendment,2015-01-29 07:00:00-05:00,VVUS,positive
1332160.0,Benzinga's Top #PreMarket Gainers,2015-01-23 08:15:00-05:00,VVUS,positive
1332161.0,Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit Tops Expectations,2015-01-21 10:42:00-05:00,VVUS,positive
1332162.0,5 Obesity Stocks Investors Are Watching,2015-01-14 13:55:00-05:00,VVUS,neutral
1332163.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4,2015-01-13 11:34:00-05:00,VVUS,neutral
1332164.0,Stocks Hitting 52-Week Lows,2014-12-30 10:31:00-05:00,VVUS,negative
1332165.0,Orexigen Therapeutics Gains On Diet Pill Nod From European Committee,2014-12-19 14:09:00-05:00,VVUS,positive
1332166.0,Pharmaceutical Stocks In Play Following Merck/Cubist Deal,2014-12-08 09:09:00-05:00,VVUS,positive
1332167.0,VIVUS Announces Issuance Of Two Additional U.S. Patents For Qsymia,2014-11-26 07:01:00-05:00,VVUS,neutral
1332168.0,What's Driving Orexigen Therapeutics Higher?,2014-11-13 12:10:00-05:00,VVUS,neutral
1332169.0,"Banl Maintains Underperform on VIVUS, Inc., Lowers PT to $3.00",2014-11-06 05:15:00-05:00,VVUS,negative
1332170.0,"VIVUS, Inc. Reports Q3 EPS of $(0.15) vs $(0.25) Est; Revenue of $33.90M vs $21.85M Est",2014-11-05 16:25:00-05:00,VVUS,neutral
1332171.0,"Earnings Scheduled For November 5, 2014",2014-11-05 05:05:00-05:00,VVUS,neutral
1332172.0,3 Pharma Companies Fighting Obesity,2014-10-30 14:00:00-04:00,VVUS,negative
1332173.0,Bank Of America Q3 Small & Mid-Cap Biotech Preview,2014-10-20 16:58:00-04:00,VVUS,neutral
1332174.0,"Vivus, Inc. Opens Sharply Higher On ED Drug Marketing Approval",2014-09-18 09:55:00-04:00,VVUS,positive
1332175.0,Morning Market Movers ,2014-09-18 09:46:00-04:00,VVUS,neutral
1332176.0,UPDATE: VIVUS Shares Rise 20% Premarket on Announcement of FDA Approval Of STENDRA sNDA,2014-09-18 08:16:00-04:00,VVUS,positive
1332177.0,Benzinga's Top #PreMarket Gainers,2014-09-18 08:05:00-04:00,VVUS,positive
1332178.0,"US Stock Futures Up Ahead Of Jobless Claims, Housing Starts Data",2014-09-18 07:10:00-04:00,VVUS,neutral
1332179.0,VIVUS Auxilium Announce FDA Approval Of STENDRA sNDA,2014-09-18 06:07:00-04:00,VVUS,positive
1332180.0,Vivus Spikes Lower,2014-09-15 15:47:00-04:00,VVUS,negative
1332181.0,"FDA Panel Says Novo Nordisk's Liraglutide is Safe, Effective for Chronically Obese Patients",2014-09-11 15:57:00-04:00,VVUS,positive
1332182.0,"VIVUS Announces Purchase of Topiramate-Related Patents from J&J's Janssen Pharma, Will Dismiss Suit Against VIVUS",2014-08-25 07:12:00-04:00,VVUS,neutral
1332183.0,"VIVUS, Inc. Reports Q2 EPS of $(0.25) vs $(0.28) Est; Revenue of $21.90M vs $17.90M Est",2014-08-07 16:11:00-04:00,VVUS,neutral
1332184.0,"Stocks To Watch For June 16, 2014",2014-06-16 08:02:00-04:00,VVUS,neutral
1332185.0,"UPDATE: VIVUS Reports Suit Aaainst Actavis, Cites Infringement of Qsymia Patents",2014-06-12 16:35:00-04:00,VVUS,negative
1332186.0,"VIVUS Reports Suit Aaainst Actavis, Cites Infringement of Qsymia Patents",2014-06-12 16:34:00-04:00,VVUS,negative
1332187.0,Orexigen Shares Plummet Following FDA Decision; Competition Gets A Bump,2014-06-11 11:24:00-04:00,VVUS,positive
1332188.0,Is Vivus About To Get Squeezed?,2014-06-09 14:54:00-04:00,VVUS,neutral
1332189.0,"Stocks To Watch For June 09, 2014",2014-06-09 07:46:00-04:00,VVUS,neutral
1332190.0,"Stocks To Watch For June 06, 2014",2014-06-06 07:39:00-04:00,VVUS,neutral
1332191.0,"Option Alert: Vivus Dec $7 Call; 8,500 Contract Trade at Ask @$0.35 vs 578 OI; Currently $5.05",2014-06-04 13:44:00-04:00,VVUS,positive
1332192.0,"Stocks To Watch For May 29, 2014",2014-05-29 07:49:00-04:00,VVUS,neutral
1332193.0,"Benzinga's M&A Chatter for Wednesday May 28, 2014",2014-05-28 18:02:00-04:00,VVUS,neutral
1332194.0,Wells Fargo Analyst Issues Note Suggesting a Deal for Vivus Would Not Necessarily Help Address Potential Issues with Qsymia,2014-05-28 12:14:00-04:00,VVUS,negative
1332195.0,"Aspen Buys 9.65% Stake In Vivus, May Acquire Added Holdings",2014-05-28 12:02:00-04:00,VVUS,neutral
1332196.0,Shares of VIVUS Up 13+% Following 13D Filing from Aspen Investment Fund,2014-05-28 09:57:00-04:00,VVUS,positive
1332197.0,"13D Filing from Aspen Investment Fund on VIVUS Shows 9.65% Stake, Includes Language Will 'Have Talks with Mgmt, Board,' Expects to Make an Offer",2014-05-28 09:55:00-04:00,VVUS,neutral
1332198.0,Form 8-K from VIVUS Shows Actavis Has Filed ANDA for Generic Version of Qsymia,2014-05-09 07:03:00-04:00,VVUS,neutral
1332199.0,Benzinga's Top #PreMarket Gainers,2014-05-06 08:06:00-04:00,VVUS,positive
1332200.0,"VIVUS, Inc. Reports Q1 EPS of $(0.15) vs $(0.37) Est; Revenue of $36.70M vs $11.40M Est",2014-05-05 16:00:00-04:00,VVUS,neutral
1332201.0,"Stocks To Watch For May 05, 2014",2014-05-05 12:27:00-04:00,VVUS,neutral
1332202.0,"Option Alert: Vivus Sep $6 Call; 10,288 Contracts Traded vs 681 OI; Currently $5.31",2014-04-22 12:29:00-04:00,VVUS,positive
1332203.0,"VIVUS Says Three Directors (Carroll, Logan, Wilson) Will Not Stand for Reelection",2014-04-08 17:01:00-04:00,VVUS,neutral
1332204.0,Shares of Vivus Fall +10% Following Piper Jaffray's Downgrade,2014-04-03 13:03:00-04:00,VVUS,positive
1332205.0,Mid-Day Market Update: US Stocks Fall; Google Shares Rise After Stock Split,2014-04-03 12:41:00-04:00,VVUS,positive
1332206.0,Mid-Morning Market Update: Markets Mostly Flat; Greenbrier Results Beat Estimates,2014-04-03 10:43:00-04:00,VVUS,neutral
1332207.0,Morning Market Losers ,2014-04-03 09:49:00-04:00,VVUS,negative
1332208.0,Benzinga's Top #PreMarket Losers,2014-04-03 08:29:00-04:00,VVUS,negative
1332209.0,Benzinga's Top Downgrades,2014-04-03 07:47:00-04:00,VVUS,positive
1332210.0,"Piper Jaffray Downgrades VIVUS, Inc. to Underweight, Lowers PT to $3.00",2014-04-03 07:29:00-04:00,VVUS,negative
1332211.0,Vivus Announces Review Article Summarizing Cardiovascular Benefit-Risk Profile of Qsymia,2014-03-25 07:50:00-04:00,VVUS,neutral
1332212.0,Market Wrap For February 25: Markets End The Day Relatively Flat,2014-02-25 16:38:00-05:00,VVUS,neutral
1332213.0,Mid-Afternoon Market Update: Markets Turn Red as Tesla Continues to Rip Higher,2014-02-25 15:51:00-05:00,VVUS,neutral
1332214.0,Mid-Day Market Update: US Stocks Mostly Flat; Office Depot Shares Decline On Q4 Results,2014-02-25 13:07:00-05:00,VVUS,positive
1332215.0,Mid-Morning Market Update: Markets Fall; Home Depot Profit Beats Estimates,2014-02-25 11:44:00-05:00,VVUS,positive
1332216.0,UPDATE: Vivus Down Nearly 12% After JP Morgan Downgrade on Lackluster Qsymia News,2014-02-25 11:30:00-05:00,VVUS,positive
1332217.0,Stocks Hitting 52-Week Lows,2014-02-25 10:21:00-05:00,VVUS,negative
1332218.0,"Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, BCRX Moving Higher, RP, ODP, VVUS, AINV, MGIC, ALSN Lower",2014-02-25 09:41:00-05:00,VVUS,negative
1332219.0,Benzinga's Top #PreMarket Losers,2014-02-25 08:14:00-05:00,VVUS,negative
1332220.0,UPDATE: Bank of America Downgrades Vivus as Partnering Prospects Weaken,2014-02-25 08:12:00-05:00,VVUS,negative
1332221.0,Benzinga's Top Downgrades,2014-02-25 07:46:00-05:00,VVUS,positive
1332222.0,US Stock Futures Slip Ahead Of Economic Data,2014-02-25 07:22:00-05:00,VVUS,neutral
1332223.0,"JP Morgan Downgrades VIVUS, Inc. to Neutral, Lowers PT to $8.00",2014-02-25 06:58:00-05:00,VVUS,positive
1332224.0,"Bank of America Downgrades VIVUS, Inc. to Underperform, Lowers PO to $6.00",2014-02-25 06:41:00-05:00,VVUS,negative
1332225.0,"VIVUS, Inc. Reports Q4 EPS of $(0.17) vs $(0.40) Est; Revenue of $44.10M vs $28.20M Est",2014-02-24 16:00:00-05:00,VVUS,neutral
1332226.0,"VIVUS, Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA",2014-01-21 07:01:00-05:00,VVUS,positive
1332227.0,Benzinga's Top #PreMarket Gainers,2014-01-14 08:09:00-05:00,VVUS,positive
1332228.0,VIVUS Announces Will Collaborate with Aetna to Test First Comprehensive Weight Mgmt Program Integrating Weight Loss Medication,2014-01-14 07:04:00-05:00,VVUS,negative
1332229.0,Vivus Enters Pact With CaremarkPCS Health,2014-01-02 07:12:00-05:00,VVUS,neutral
1332230.0,Form 8-K from VIVUS Shows Co. Says CHMP Feedback on Aqclaim/OB-401 'Generally Positive',2013-12-27 16:12:00-05:00,VVUS,positive
1332231.0,"UPDATE: Vivus Eligible to Receive Up to $61M in Upfront Payments, Regulatory and Sales Milestones; Will Also Receive Escalating Royalties Based Net Sales During Agreement",2013-12-12 07:06:00-05:00,VVUS,positive
1332232.0,"VIVUS Announces License and Commercialization Agreement With Sanofi for Avanafil in Africa, Middle East, Turkey and CIS/Russia ",2013-12-12 07:01:00-05:00,VVUS,positive
1332233.0,"Form 8-K from VIVUS Shows Co. Entered Manufacturing & Supply Deal with Sanofi Winthrop, Pact is for Semi-Exclusive Basis in Europe and LatAm",2013-11-21 16:13:00-05:00,VVUS,neutral
1332234.0,"Annaly Capital, VIVUS And Others Insiders Have Been Buying",2013-11-15 14:48:00-05:00,VVUS,neutral
1332235.0,"Wallachbeth Initiates Coverage on VIVUS, Inc. at Hold, Announces $11.00 PT",2013-11-15 07:42:00-05:00,VVUS,neutral
1332236.0,VIVUS Awarded Two US Patents for Qsymia; Patent Coverage for Qsymia Extended to 2029 ,2013-11-13 07:03:00-05:00,VVUS,positive
1332237.0,Stocks Hitting 52-Week Lows,2013-11-06 10:20:00-05:00,VVUS,negative
1332238.0,UPDATE: Bank of America Downgrades Vivus on Weaker Partnering Prospects,2013-11-06 09:09:00-05:00,VVUS,negative
1332239.0,Benzinga's Top Downgrades,2013-11-06 07:57:00-05:00,VVUS,positive
1332240.0,US Stock Futures Up Ahead Of Time Warner Earnings,2013-11-06 07:08:00-05:00,VVUS,neutral
1332241.0,"Bank of America Downgrades VIVUS, Inc. to Neutral, Lowers PO to $11.00",2013-11-06 06:24:00-05:00,VVUS,negative
1332242.0,"VIVUS, Inc. Reports Q3 EPS of $(0.48) vs $(0.38) Est; Revenue of $6.40M vs $21.78M Est",2013-11-05 16:00:00-05:00,VVUS,neutral
1332243.0,VIVUS Announces Newly Published Study Finds Qsymia Achieves Greater Weight Loss at Lower Doses Than Either of Its Components as Monotherapy,2013-10-31 07:25:00-04:00,VVUS,negative
1332244.0,Vivus Spikes Higher,2013-10-28 11:00:00-04:00,VVUS,neutral
1332245.0,"Option Alert: Vivus January 11 Call; 7,836 Contracts Traded @$0.53; Currently $9.46",2013-10-23 10:50:00-04:00,VVUS,positive
1332246.0,Vivus Spikes Higher,2013-10-23 10:20:00-04:00,VVUS,neutral
1332247.0,UPDATE: Piper Jaffray Downgrades VIVUS Following Management Meetings,2013-10-16 12:52:00-04:00,VVUS,neutral
1332248.0,Benzinga's Top Pre-Market Losers,2013-10-16 08:19:00-04:00,VVUS,negative
1332249.0,"Piper Jaffray Downgrades VIVUS, Inc. to Neutral",2013-10-16 07:05:00-04:00,VVUS,neutral
1332250.0,"Form 8-K from Vivus Discloses Presentation Slides 'Innovative Therapies, Novel Products'",2013-10-15 07:24:00-04:00,VVUS,positive
1332251.0,"Clinton Group Sends Letter to VIVUS CEO, Says Co. Should Do More to Give Info on Strength of 2020 Patents",2013-10-11 08:31:00-04:00,VVUS,positive
1332252.0,"Auxilium Pharmaceuticals Announces License Agreement with Vivus for Marketing Rights to STENDRA In US, Canada ",2013-10-11 07:07:00-04:00,VVUS,positive
1332253.0,Benzinga's Top Pre-Market Gainers,2013-10-09 08:10:00-04:00,VVUS,positive
1332254.0,"VIVUS Says Qsymia Shown to Reduce Progression to Type 2 Diabetes in High-Risk Overweight Patients, Was Well Tolerated by Subgroup Over Two Years",2013-10-08 18:07:00-04:00,VVUS,negative
1332255.0,"Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and Raises PT",2013-10-03 16:42:00-04:00,VVUS,neutral
1332256.0,Mid-Day Market Update: Dow Slips Below 15000; CalAmp Jumps On Upbeat Results,2013-10-03 12:11:00-04:00,VVUS,neutral
1332257.0,Benzinga's Volume Movers,2013-10-03 10:45:00-04:00,VVUS,neutral
1332258.0,Mid-Morning Market Update: Markets Open Lower; Constellation Brands Profit Beats Estimates,2013-10-03 10:34:00-04:00,VVUS,positive
1332259.0,Benzinga's Top Pre-Market Gainers,2013-10-03 08:12:00-04:00,VVUS,positive
1332260.0,Benzinga's Top Upgrades,2013-10-03 07:50:00-04:00,VVUS,positive
1332261.0,"Cowen & Company Upgrades VIVUS, Inc. to Outperform, Announces $19.00 PT",2013-10-03 07:08:00-04:00,VVUS,neutral
1332262.0,VIVUS Says Pres Peter Tam Resigns,2013-09-27 17:15:00-04:00,VVUS,negative
1332263.0,Stocks Hitting 52-Week Lows,2013-09-24 10:44:00-04:00,VVUS,negative
1332264.0,"Piper Jaffray Cuts Target on VIVUS from $20 to $14, Maintains Overweight",2013-09-12 09:27:00-04:00,VVUS,negative
1332265.0,"BMO Considers Recent Sales Data on Arena's Belviq, Maintains Market Perform Rating",2013-09-09 14:11:00-04:00,VVUS,neutral
1332266.0,"Duke Energy, VIVUS And Others Insiders Have Been Buying",2013-09-07 15:22:00-04:00,VVUS,positive
1332267.0,Benzinga's Top Downgrades,2013-09-04 07:49:00-04:00,VVUS,positive
1332268.0,"Lazard Capital Markets Downgrades VIVUS, Inc. to Sell",2013-09-04 07:44:00-04:00,VVUS,neutral
1332269.0,"VIVUS Reports Incumbent CEO Has Resigned Amid Health Issues, Co. Names Seth Fischer as CEO",2013-09-03 07:07:00-04:00,VVUS,negative
1332270.0,"Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)",2013-08-27 13:29:00-04:00,VVUS,positive
1332271.0,"VIVUS, Inc. Reports Q2 EPS of $(0.55) vs $(0.44) Est; Revenue of $5.53M vs $12.76M Est",2013-08-06 16:31:00-04:00,VVUS,neutral
1332272.0,Adam F Tweets Vivus Weight-Loss Scripts Surging,2013-07-30 10:27:00-04:00,VVUS,neutral
1332273.0,"Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)",2013-07-26 10:46:00-04:00,VVUS,positive
1332274.0,"VIVUS Board Names Michael Astrue as Chairman, Tony Zook as CEO ",2013-07-23 06:25:00-04:00,VVUS,neutral
1332275.0,"Needham Downgrades VIVUS, Inc. to Hold",2013-07-19 10:32:00-04:00,VVUS,neutral
1332276.0,QVT Financial Reporting New 8.28% Stake In Vivus,2013-07-19 08:33:00-04:00,VVUS,neutral
1332277.0,"VIVUS, First Manhattan, Sarissa Capital Announce Settlement Agreement Related to Proxy Contest",2013-07-19 05:56:00-04:00,VVUS,positive
1332278.0,"Bloomberg Reporting Vivus Agrees to Change CEO, Give In to First Manhattan",2013-07-18 16:45:00-04:00,VVUS,positive
1332279.0,First Manhattan Continues to Seek Fair Settlement ,2013-07-17 13:10:00-04:00,VVUS,positive
1332280.0,A Peek Into The Market Before The Trading Starts,2013-07-17 07:41:00-04:00,VVUS,neutral
1332281.0,First Manhattan Rejects VIVUS Proposal,2013-07-17 06:00:00-04:00,VVUS,negative
1332282.0,VIVUS Says First Manhattan Made False and Misleading Statements,2013-07-16 19:52:00-04:00,VVUS,negative
1332283.0,First Manhattan Continues to Seek Settlement Despite Bad Faith Negotiating Tactics from Vivus' Existing Board ,2013-07-16 14:14:00-04:00,VVUS,positive
1332284.0,First Manhattan Issues Statement: Objects to Adjournment of VIVUS Annual Meeting,2013-07-15 13:56:00-04:00,VVUS,neutral
1332285.0,UPDATE: Credit Suisse Downgrades Vivus on Valuation,2013-07-15 09:32:00-04:00,VVUS,positive
1332286.0,Benzinga's Top Pre-Market Losers,2013-07-15 08:19:00-04:00,VVUS,negative
1332287.0,"Credit Suisse Downgrades VIVUS, Inc. to Neutral, Maintains PT to $15.00",2013-07-15 07:27:00-04:00,VVUS,positive
1332288.0,First Manhattan Responds to Adjournment of Annual Meeting by Vivus Board,2013-07-15 05:50:00-04:00,VVUS,neutral
1332289.0,Vivus Reports First Manhattan's False and Misleading Statements to SEC,2013-07-14 22:44:00-04:00,VVUS,negative
1332290.0,VIVUS Offers Compromise to First Manhattan,2013-07-14 09:28:00-04:00,VVUS,neutral
1332291.0,"Vivus Said to Tell Investors it's Open to Dissident Settlement, Vivus in Proxy Fight with Largest Shareholder First Manhattan",2013-07-12 15:05:00-04:00,VVUS,negative
1332292.0,"Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)",2013-07-11 12:47:00-04:00,VVUS,positive
1332293.0,First Manhattan Urges Vivus Shareholders to Elect Nine New Independent Directors ,2013-07-11 06:41:00-04:00,VVUS,neutral
1332294.0,"VIVUS Issues Statement Ahead of Annual Holder Meeting, Says In Pact with Menarini Group for Spedra",2013-07-10 07:16:00-04:00,VVUS,neutral
1332295.0,VIVUS Board Responds to First Manhattan,2013-07-09 07:01:00-04:00,VVUS,neutral
1332296.0,First Manhattan Reminds Vivus Shareholders That Time is Running out to Save Vivus ,2013-07-08 13:38:00-04:00,VVUS,positive
1332297.0,"First Manhattan Says ISS, Egan-Jones Recommend Vivus Shareholders to Vote For Board Nominees, ISS Endorses 3, Egan-Jones Endorses All 9",2013-07-05 11:52:00-04:00,VVUS,positive
1332298.0,A Peek Into The Market Before The Trading Starts ,2013-07-05 07:35:00-04:00,VVUS,neutral
1332299.0,"ISS, Glass Lewis Reject FMC's Attempt to Take Control of VIVUS's Board ",2013-07-05 07:01:00-04:00,VVUS,negative
1332300.0,"ISS, Egan Jones Recommend Vivus Stockholders Vote for First Manhattan's Board Nominees",2013-07-05 06:04:00-04:00,VVUS,positive
1332301.0,First Manhattan Announces That Anthony Zook Has Agreed to Serve as Vivus CEO If Its Director Nominees Are Elected ,2013-07-02 07:32:00-04:00,VVUS,positive
1332302.0,VIVUS Mails Letter to Stockholders In Response to First Manhattan Claims,2013-07-02 07:03:00-04:00,VVUS,neutral
1332303.0,VIVUS Announces Availability of Qsymia,2013-07-01 07:03:00-04:00,VVUS,neutral
1332304.0,Investor First Manhattan Issues Update to VIVUS Shareholders,2013-06-28 14:52:00-04:00,VVUS,neutral
1332305.0,VIVUS Clarifies Misstatements by First Manhattan ,2013-06-28 07:01:00-04:00,VVUS,positive
1332306.0,VIVUS Sends Letter to Shareholders In Response to First Manhattan,2013-06-27 07:01:00-04:00,VVUS,neutral
1332307.0,"Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)",2013-06-26 13:17:00-04:00,VVUS,positive
1332308.0,VIVUS Announces SPEDRA (avanafil) Approval in Europe ,2013-06-26 13:01:00-04:00,VVUS,positive
1332309.0,Vivus Spikes Higher,2013-06-26 13:00:00-04:00,VVUS,neutral
1332310.0,First Manhattan Outlines Strategic Plan to Fix VIVUS ,2013-06-25 12:54:00-04:00,VVUS,neutral
1332311.0,VIVUS Comments on Sam Colin's Questionable Claims ,2013-06-25 07:01:00-04:00,VVUS,negative
1332312.0,"Stocks to Watch for June 24, 2013",2013-06-24 09:42:00-04:00,VVUS,neutral
1332313.0,First Manhattan Offers Letter to VIVUS,2013-06-24 08:02:00-04:00,VVUS,neutral
1332314.0,"Senators Carper, Murkowski, Representatives Cassidy, Kind Introduce Bill to Help Reduce Obesity",2013-06-19 12:47:00-04:00,VVUS,positive
1332315.0,Hearing Chatter of Lawmakers Introducing Bill to Require Medicare to Cover Weight-Loss Drugs,2013-06-19 12:09:00-04:00,VVUS,neutral
1332316.0,VIVUS Reports Study Results Demonstrating STENDRA Effective for Sexual Activity within 15 Mins in Men with ED,2013-06-19 07:05:00-04:00,VVUS,positive
1332317.0,VIVUS Study Shows STENDRA is Effective for Sexual Activity Within 15 Minutes in Men With ED,2013-06-19 07:03:00-04:00,VVUS,positive
1332318.0,"VIVUS Tells Holders to Support Board, Management Team",2013-06-17 07:26:00-04:00,VVUS,positive
1332319.0,"Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)",2013-06-12 13:29:00-04:00,VVUS,positive
1332320.0,Article Cites Vivus' Qsymia for Weight Management in People With Type 2 Diabetes ,2013-06-07 07:03:00-04:00,VVUS,neutral
1332321.0,"First Manhattan Mails Definitive Proxy Statement, Sends Letter to VIVUS Holders, Seeks to Have Nine Nominees Elected to Board",2013-06-04 11:21:00-04:00,VVUS,neutral
1332322.0,Vivus Director E. Mario Has Purchases 15K Shares of the Company's Stock,2013-05-30 13:59:00-04:00,VVUS,positive
1332323.0,"Short Interest in Vertex Rises, in Biogen Idec Falls",2013-05-29 13:19:00-04:00,VVUS,positive
1332324.0,"Stocks to Watch for May 23, 2013",2013-05-23 10:28:00-04:00,VVUS,neutral
1332325.0,"Vivus Prices Offering of $22M in 4.5% Convertible Senior Notes, Says Conversion Rate ~$14.86/Share",2013-05-16 07:03:00-04:00,VVUS,neutral
1332326.0,Vivus Announces $200M Convertible Senior Notes Offering,2013-05-15 07:06:00-04:00,VVUS,neutral
1332327.0,Vivus Downgraded Earlier by Lazard on News of Poorly Performing Treatment,2013-05-14 13:09:00-04:00,VVUS,neutral
1332328.0,"Stocks to Watch for May 14, 2013",2013-05-14 10:41:00-04:00,VVUS,neutral
1332329.0,"Lazard Capital Markets Downgraded VIVUS, Inc. to Neutral",2013-05-14 09:51:00-04:00,VVUS,neutral
1332330.0,"VIVUS CEO Issues Letter to Holders, Says In Discussions with Large Pharma Cos.",2013-05-13 07:07:00-04:00,VVUS,neutral
1332331.0,"Short Interest in Vertex Rises, in Celgene Falls",2013-05-11 10:45:00-04:00,VVUS,positive
1332332.0,"Stocks to Watch for May 9, 2013",2013-05-09 09:10:00-04:00,VVUS,neutral
1332333.0,"VIVUS, Inc. Reports Q1 EPS of $(0.53) vs $(0.51) Est; Revenue of $4.11M vs $5.22M Est",2013-05-08 07:36:00-04:00,VVUS,neutral
1332334.0,"Benzinga Market Primer: Wednesday, May 8",2013-05-08 06:27:00-04:00,VVUS,neutral
1332335.0,"Earnings Scheduled For May 8, 2013",2013-05-08 04:53:00-04:00,VVUS,neutral
1332336.0,First Manhattan Releases Case for Full Board Change at Vivus ,2013-05-07 16:19:00-04:00,VVUS,neutral
1332337.0,"The Week Ahead: Host of Earnings on Tap; Investors Watching Anadarko, Activision, and Whole Foods",2013-05-03 18:43:00-04:00,VVUS,neutral
1332338.0,"First Manhattan Responds to VIVUS Board Additions, Says Board Still Needs Overhaul",2013-05-01 08:49:00-04:00,VVUS,neutral
1332339.0,"Vivus Shares Volatile as Traders Responding to Piper Jaffray Note Says Qsymia Could Get Medicare, Aetna-Related Updates",2013-04-30 11:35:00-04:00,VVUS,positive
1332340.0,"VIVUS Names Robert Wilson to Board; Says Entered Into Commercial Rebate Pact with Medco April, Patients to Pay Estimated $50-60 Copay",2013-04-30 07:09:00-04:00,VVUS,negative
1332341.0,"Short Sellers Move into Celgene, Regeneron",2013-04-26 13:25:00-04:00,VVUS,neutral
1332342.0,"Vivus Reports 23,812 Qsymia Prescriptions Shipped for Month Ended March 31, 2013 vs 18,417 for Month Ended February 28, 2013 -8-K",2013-04-19 06:12:00-04:00,VVUS,neutral
1332343.0,"Stocks to Watch for April 18, 2013",2013-04-18 08:36:00-04:00,VVUS,neutral
1332344.0,VIVUS Announces FDA Approval of Qsymia REMS Modification Allowing Access Through Certified Retail Pharmacies,2013-04-16 14:31:00-04:00,VVUS,positive
1332345.0,"Vivus, Arena Spike Higher",2013-04-16 14:31:00-04:00,VVUS,neutral
1332346.0,Technical Setups for the Week Ahead,2013-04-15 09:25:00-04:00,VVUS,neutral
1332347.0,ETF Showdown: A Pharma Fight,2013-04-11 16:21:00-04:00,VVUS,negative
1332348.0,"Stocks to Watch for April 11, 2013",2013-04-11 08:54:00-04:00,VVUS,neutral
1332349.0,"Short Sellers Move Out of Amgen, Celgene, Pharmacyclics",2013-04-10 13:30:00-04:00,VVUS,neutral
1332350.0,First Manhattan Says Expects VIVUS Announcement on QSYMIA,2013-04-10 09:26:00-04:00,VVUS,neutral
1332351.0,"Short Sellers Dump Amgen, Focus on Celgene, Gilead Sciences",2013-03-28 08:18:00-04:00,VVUS,negative
1332352.0,A Peek Into The Market Before The Trading Starts,2013-03-26 07:15:00-04:00,VVUS,neutral
1332353.0,VIVUS Enters into $110M Non-Equity Financing,2013-03-26 06:34:00-04:00,VVUS,neutral
1332354.0,"Option Alert: Vivus January 2014 10 Put; Block Trade: 9,100 Contracts @$2.10; Currently $11.23",2013-03-14 11:29:00-04:00,VVUS,negative
1332355.0,"Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)",2013-03-12 13:19:00-04:00,VVUS,positive
1332356.0,VIVUS Confirms Receipt of Notice of Nomination from First Manhattan Co.,2013-03-08 15:16:00-05:00,VVUS,neutral
1332357.0,"VIVUS Shares to Open Higher as First Manhattan Showing 8.8% Stake, Says Intends to Nominate Six Directors to Board",2013-03-08 09:25:00-05:00,VVUS,positive
1332358.0,UPDATE: Piper Jaffray Initiates VIVUS with Overweight on New Category Challenges,2013-03-06 08:51:00-05:00,VVUS,negative
1332359.0,"Piper Jaffray Initiates Coverage on VIVUS, Inc. at Overweight, Announces $17.00 PT",2013-03-05 16:10:00-05:00,VVUS,negative
1332360.0,"VIVUS Unveils New Offer for Qsymia, to Last for No More Than $75 Per 30 Days",2013-03-05 07:07:00-05:00,VVUS,negative
1332361.0,"Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)",2013-02-28 15:13:00-05:00,VVUS,positive
1332362.0,"Mid-Afternoon Market Update: Markets Go Positive Across the Board, Home Builders Rise",2013-02-26 15:54:00-05:00,VVUS,positive
1332363.0,"Mid-Day Market Update: Cracker Barrel Surges On Upbeat Results, VIVUS Drops",2013-02-26 12:44:00-05:00,VVUS,neutral
1332364.0,"UPDATE: Jefferies Cuts PT to $5, on VIVUS on Qsymia Shortfall, Higher Expenses",2013-02-26 12:17:00-05:00,VVUS,negative
1332365.0,UPDATE: Bank of America Cuts PO to $24 on VIVUS on Sluggish Qsymia Launch,2013-02-26 11:36:00-05:00,VVUS,negative
1332366.0,UPDATE: JP Morgan Cuts PT to $22 on VIVUS Following Q4 Report,2013-02-26 09:15:00-05:00,VVUS,positive
1332367.0,"Jefferies Maintains Underperform on VIVUS, Inc., Lowers PT to $5.00",2013-02-26 08:28:00-05:00,VVUS,negative
1332368.0,"Bank of America Maintains Buy on VIVUS, Inc., Lowers PO to $24.00",2013-02-26 08:11:00-05:00,VVUS,negative
1332369.0,"JP Morgan Maintains Overweight on VIVUS, Inc., Lowers PT to $22.00",2013-02-26 07:56:00-05:00,VVUS,negative
1332370.0,"VIVUS, Inc. Reports Q4 EPS of $(0.56) vs $(0.44) Est; Revenue of $1.97M vs $3.09M Est",2013-02-25 16:14:00-05:00,VVUS,neutral
1332371.0,"Benzinga Market Primer: Monday, February 25",2013-02-25 06:18:00-05:00,VVUS,neutral
1332372.0,"Earnings Scheduled For February 25, 2013",2013-02-25 04:22:00-05:00,VVUS,neutral
1332373.0,"The Week Ahead: Earnings from JC Penney, Groupon, Salesforce",2013-02-22 17:16:00-05:00,VVUS,neutral
1332374.0,"UPDATE: Bank of America Reiterates Buy Rating, Lowers PT on Vivus on Failed Qsiva Appeal",2013-02-22 14:45:00-05:00,VVUS,negative
1332375.0,"VIVUS Says EMA Confirmed Oct. MAA Decline, Wants Cardio Outcomes Trial on Qsiva",2013-02-21 17:01:00-05:00,VVUS,neutral
1332376.0,"Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)",2013-02-12 13:29:00-05:00,VVUS,positive
1332377.0,Potential Setups For Next Week,2013-02-11 16:03:00-05:00,VVUS,neutral
1332378.0,Wednesday February 6th Watchlist,2013-02-06 12:54:00-05:00,VVUS,neutral
1332379.0,"Leerink Swann Resumed Outperform Rating on VIVUS, Inc.",2013-02-06 10:07:00-05:00,VVUS,neutral
1332380.0,VIVUS Announces Publication of Positive Study  on Qsymia,2013-02-01 07:03:00-05:00,VVUS,positive
1332381.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",2013-01-26 12:17:00-05:00,VVUS,positive
1332382.0,Pharmas Look to Fatten Up With Obesity Drugs,2013-01-24 13:25:00-05:00,VVUS,neutral
1332383.0,Trading The News,2013-01-18 12:02:00-05:00,VVUS,neutral
1332384.0,"UPDATE: First Manhattan Showing 7.2% Stake in VIVUS, Had 4.85% Stake as of Sept. 30th",2013-01-18 09:24:00-05:00,VVUS,neutral
1332385.0,First Manhattan Files 13D on VIVUS,2013-01-18 09:23:00-05:00,VVUS,neutral
1332386.0,"Brean Capital Downgrades VIVUS, Inc. to Sell, Announces $7.00 PT",2013-01-17 07:51:00-05:00,VVUS,neutral
1332387.0,Wednesday January 16th watchlist,2013-01-16 17:02:00-05:00,VVUS,neutral
1332388.0,Vivus Spokesperson Says Volatility in Vivus Shares on Mondays Due to Release of Qsymia Script Data from 3rd-Party Sources,2013-01-14 10:26:00-05:00,VVUS,positive
1332389.0,Hearing Unconfirmed Market Chatter in Vivus,2013-01-14 10:21:00-05:00,VVUS,negative
1332390.0,"Benzinga's M&A Chatter for Tuesday January 8, 2013",2013-01-08 20:07:00-05:00,VVUS,neutral
1332391.0,"UPDATE: Deal Reporter Says Vivus CEO Says Co Could be Acquired, Talks Ongoing",2013-01-08 12:01:00-05:00,VVUS,neutral
1332392.0,Vivus Spikes Higher on Deal Reporter Story Regarding CEO Comments,2013-01-08 11:59:00-05:00,VVUS,neutral
1332393.0,Tuesday January 8th watchlist,2013-01-08 08:28:00-05:00,VVUS,neutral
1332394.0,"Mid-Day Market Update: SolarCity Wins Big, SunPower Continues its Fall",2013-01-07 13:10:00-05:00,VVUS,positive
1332395.0,BofA Earlier Added Vivus Shares to the Firm's 'US 1' List,2013-01-07 12:30:00-05:00,VVUS,positive
1332396.0,"Mid-Morning Market Update: Markets Giving Back Some Gains, Big Banks Catch a Break",2013-01-07 10:36:00-05:00,VVUS,positive
1332397.0,Benzinga's Top Pre-Market Gainers,2013-01-07 08:12:00-05:00,VVUS,positive
1332398.0,Vivus Rises 9% Pre-Market; Releases Slides from JP Morgan Healthcare Conference Presentation in 8K Filing,2013-01-07 08:07:00-05:00,VVUS,positive
1332399.0,"Mid-Afternoon Market Update: Markets Rally Further, VIVUS Remains Down",2013-01-02 15:37:00-05:00,VVUS,neutral
1332400.0,"Mid-Day Market Update: Markets Continue Rally, Dole Falls",2013-01-02 13:22:00-05:00,VVUS,neutral
1332401.0,"Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)",2012-12-28 11:10:00-05:00,VVUS,positive
1332402.0,"Mid-Morning Market Update: Rite Aid Rallies, New York Stock Exchange Acquired by ICE",2012-12-20 10:35:00-05:00,VVUS,neutral
1332403.0,VIVUS Shares Edge Higher as Express Scripts Adds Qsymia to Benefits Program,2012-12-20 09:58:00-05:00,VVUS,positive
1332404.0,Tuesday December 18th watchlist,2012-12-18 08:20:00-05:00,VVUS,neutral
1332405.0,Vivus Rallies on Prescription Increase,2012-12-17 17:38:00-05:00,VVUS,positive
1332406.0,"Mid-Afternoon Market Update: Compuware Holds Onto Gains, Clearwire Remains Down",2012-12-17 15:45:00-05:00,VVUS,positive
1332407.0,Mid-Day Market Update: Compuware Rises; Nam Tai Electronics Drops,2012-12-17 14:40:00-05:00,VVUS,neutral
1332408.0,Mid-Morning Market Update: Caribou Bought Out; Clearwire Plummets,2012-12-17 11:31:00-05:00,VVUS,neutral
1332409.0,VIVUS Shares Open ~8% Higher as Bloomberg Article Highlights 46% Weekly Rise in Prescriptions for the Company's Diet Drug,2012-12-17 09:35:00-05:00,VVUS,positive
1332410.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",2012-12-12 12:57:00-05:00,VVUS,positive
1332411.0,Acadia Pharma Rockets Higher on Study Results,2012-11-27 16:44:00-05:00,VVUS,neutral
1332412.0,Vivus Spikes to Highs,2012-11-27 12:02:00-05:00,VVUS,neutral
1332413.0,VIVUS Initiates Qsymia Get Started! Free Trial Offer Program,2012-11-26 09:06:00-05:00,VVUS,positive
1332414.0,Mid-Day Market Update: Markets Turn Upwards; Scholastic Corporation Takes a Beating,2012-11-21 13:27:00-05:00,VVUS,negative
1332415.0,Mid-Morning Market Update: Markets Largely Flat; Hostess to Continue With Liquidation,2012-11-21 11:08:00-05:00,VVUS,neutral
1332416.0,QVT Financial Shows 8.3% Stake in VIVUS; QVT Met with VIVUS CEO Urging the Sale of the Co.,2012-11-15 16:54:00-05:00,VVUS,neutral
1332417.0,Mid-Morning Market Update: Markets Start to Recover; DryShips Takes a Hit,2012-11-15 10:48:00-05:00,VVUS,neutral
1332418.0,"Lazard Maintains Vivus at Buy, Lowers PT from $31 to $27",2012-11-15 10:25:00-05:00,VVUS,negative
1332419.0,VVUS Starting Payment Assistance Program for Qsymia ,2012-11-14 13:05:00-05:00,VVUS,neutral
1332420.0,"Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)",2012-11-12 13:24:00-05:00,VVUS,positive
1332421.0, Vivus Study Finds Significant Improvements in Patients with Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules ,2012-11-12 07:19:00-05:00,VVUS,positive
1332422.0,Vivus Spikes to Highs,2012-11-09 09:47:00-05:00,VVUS,neutral
1332423.0,"Futures Flat, Euro Falls Ahead of Central Banks",2012-11-08 06:19:00-05:00,VVUS,neutral
1332424.0,"Bloomberg Notes Reduction in Analysts' Qsymia Sales Estimates: FY12 from $20M to $5M, FY13 from $200M to $83M",2012-11-07 13:04:00-05:00,VVUS,neutral
1332425.0,"UPDATE: Jefferies & Company Reiterates Underperform Rating, Lowers PT on VIVUS",2012-11-07 11:07:00-05:00,VVUS,negative
1332426.0,VIVUS Shares Hit Hard After Earnings,2012-11-07 08:30:00-05:00,VVUS,positive
1332427.0,"Jefferies & Company Maintains Vivus at Underperform, Lowers PT from $13 to $6",2012-11-07 07:09:00-05:00,VVUS,negative
1332428.0,"Bank of America Maintains Vivus at Buy, Lowers PT from $36 to $30",2012-11-06 12:57:00-05:00,VVUS,negative
1332429.0,"Option Alert: Vivus March 2013 13/20 Call; Block Trade: 8,736 Contracts @$1.15, Currently $11.13",2012-11-06 11:54:00-05:00,VVUS,negative
1332430.0,"Mid-Morning Market Update: A Nation Votes, Markets Rise",2012-11-06 10:17:00-05:00,VVUS,neutral
1332431.0,Vivus Reports Q3 EPS $-0.40 vs $-0.31 Est; Revenues $41K vs $310.00K Est,2012-11-06 08:16:00-05:00,VVUS,neutral
1332432.0,Futures Rise on Election Day,2012-11-06 06:16:00-05:00,VVUS,neutral
1332433.0,"Passport Reports 8.55M Share Stake in Vivus, Up From 8.13M",2012-11-01 14:31:00-04:00,VVUS,positive
1332434.0,John Burbank/Passport Capital Reports Increase in Vivus Stake,2012-11-01 14:15:00-04:00,VVUS,positive
1332435.0,"Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)",2012-10-25 14:09:00-04:00,VVUS,positive
1332436.0,CHMP Recommends Against Marketing Authorization Application for Vivus' Qsiva,2012-10-18 17:34:00-04:00,VVUS,positive
1332437.0,VIVUS Submits REMS Amendment To FDA For Qsymia  Capsules CIV ,2012-10-17 07:18:00-04:00,VVUS,neutral
1332438.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)",2012-10-15 06:59:00-04:00,VVUS,positive
1332439.0,"Vivus Rises 8%, Crosses $20",2012-10-08 13:47:00-04:00,VVUS,neutral
1332440.0,Express Scripts Joins Qsymia Certified Home Delivery Pharmacy Network ,2012-10-08 07:08:00-04:00,VVUS,neutral
1332441.0,A Peek Into The Market Before The Trading Starts,2012-10-03 07:30:00-04:00,VVUS,neutral
1332442.0,VIVUS Class Action Lawsuit Dismissed,2012-10-03 06:59:00-04:00,VVUS,negative
1332443.0,Arena Pharmaceuticals and VIVUS Weight Loss Drugs Approved by FDA,2012-10-02 08:30:00-04:00,VVUS,positive
1332444.0,"Jefferies & Company Maintains Vivus at Underperform, Lowers PT from $16 to $13",2012-09-24 06:39:00-04:00,VVUS,negative
1332445.0,Benzinga Mid-Afternoon Market Update ,2012-09-21 15:16:00-04:00,VVUS,neutral
1332446.0,"Bank of America  Maintains Vivus at Buy, Lowers PO from $40 to $36",2012-09-21 14:03:00-04:00,VVUS,negative
1332447.0,Benzinga Mid-Day Market Update ,2012-09-21 13:06:00-04:00,VVUS,neutral
1332448.0,Benzinga Mid-Morning Market Update,2012-09-21 10:41:00-04:00,VVUS,neutral
1332449.0,Benzinga's Top Pre-Market Losers,2012-09-21 08:55:00-04:00,VVUS,negative
1332450.0,EMA Recommends Approval of Nexobrid -Bloomberg,2012-09-21 07:36:00-04:00,VVUS,positive
1332451.0,VIVUS Says Expects EMA to Reject Qsiva Marketing,2012-09-21 07:05:00-04:00,VVUS,negative
1332452.0,Benzinga's Top Pre-Market Gainers,2012-09-18 08:25:00-04:00,VVUS,positive
1332453.0,A Peek Into The Market Before The Trading Starts,2012-09-18 07:20:00-04:00,VVUS,neutral
1332454.0,Vivus Reports Availability of Qsymia,2012-09-18 07:04:00-04:00,VVUS,neutral
1332455.0,Vivus Trading Up Over 3.4% After Announcing That Diet Pill Qsymia Is Now Available for Mail Order Sales,2012-09-17 15:09:00-04:00,VVUS,neutral
1332456.0,Short Sellers Shy Away from Biotech Firms,2012-09-13 13:34:00-04:00,VVUS,negative
1332457.0,Short Interest in Biotech Firms on the Rise,2012-08-27 15:21:00-04:00,VVUS,positive
1332458.0,"Vivus Spikes Lower, Qsymia Posted in FDA Orange Book",2012-08-21 14:16:00-04:00,VVUS,negative
1332459.0,"Option Alert: Vivus January 2013 30 Call; Block Trade: 6,830 Contracts; Currently $21.07",2012-08-20 10:23:00-04:00,VVUS,negative
1332460.0,"Social Media Outlook for Friday August 17 (FL, OPLK, VVUS, MAS)",2012-08-17 10:53:00-04:00,VVUS,neutral
1332461.0,"Jefferies Downgrades Vivus from Hold to Underperform, Lowers PT from $31 to $16",2012-08-17 08:12:00-04:00,VVUS,negative
1332462.0,Benzinga's Top Downgrades,2012-08-17 07:28:00-04:00,VVUS,positive
1332463.0,A Peek Into The Market Before The Trading Starts,2012-08-17 07:27:00-04:00,VVUS,neutral
1332464.0,Short Sellers Shy Away from Biotech Firms,2012-08-13 06:18:00-04:00,VVUS,negative
1332465.0,After-Hours: Vivus Shares Down Following Earnings Update,2012-08-07 16:44:00-04:00,VVUS,positive
1332466.0,From Earlier: Vivus Upgraded to Buy at Lazard,2012-08-07 09:25:00-04:00,VVUS,neutral
1332467.0,"Benzinga Market Primer, Monday July 30",2012-07-30 07:07:00-04:00,VVUS,neutral
1332468.0,Hearing Unconfirmed Vague Chatter in Vivus,2012-07-25 10:12:00-04:00,VVUS,negative
1332469.0,"Social Media Outlook for Friday July 20 (SNDK, BHI, CMG, LCC) ",2012-07-20 10:30:00-04:00,VVUS,neutral
1332470.0,Vivus Falls 10% on Citron Research Report,2012-07-19 13:07:00-04:00,VVUS,neutral
1332471.0,Nothing New in the Citron Report on Vivus -Adam F Tweet,2012-07-19 12:49:00-04:00,VVUS,neutral
1332472.0,Vivus Spikes Lower on Citron Research Report,2012-07-19 12:47:00-04:00,VVUS,negative
1332473.0,"Social Media Outlook for Thursday July 19 (SWKS, EBAY, MS, CTRP) ",2012-07-19 12:08:00-04:00,VVUS,neutral
1332474.0,"UPDATE: Rodman & Renshaw Reiterates Market Outperform Rating, Raises PT on Vivus",2012-07-18 13:39:00-04:00,VVUS,neutral
1332475.0,Wednesday Market Movers ,2012-07-18 12:31:00-04:00,VVUS,neutral
1332476.0,Vivus CEO Fully Expects FDA to Approve Third Obesity Drug,2012-07-18 08:56:00-04:00,VVUS,neutral
1332477.0,Vivus CEO Says Qsymia Will Be Introduced In 4Q 2012,2012-07-18 08:45:00-04:00,VVUS,negative
1332478.0,Benzinga's Top Upgrades,2012-07-18 07:18:00-04:00,VVUS,positive
1332479.0,"JP Morgan Maintains Vivus at Overweight, Raises PT from $35 to $38",2012-07-18 06:52:00-04:00,VVUS,neutral
1332480.0,"Rodman & Renshaw Maintains Vivus at Market Outperform, Raises PT to $52",2012-07-18 06:06:00-04:00,VVUS,neutral
1332481.0,"Jefferies & Company Upgrades Vivus from Underperform to Hold, Raises PT from $9 to $31",2012-07-18 05:46:00-04:00,VVUS,neutral
1332482.0,"Arena Pharmaceuticals Spiking Lower on Vivus Qnexa Approval, Orexigen Spiking Higher",2012-07-17 19:18:00-04:00,VVUS,positive
1332483.0,FDA Approves Vivus Weight-Management Drug Qsymia,2012-07-17 19:16:00-04:00,VVUS,positive
1332484.0,Vivus Spikes Lower,2012-07-17 15:33:00-04:00,VVUS,negative
1332485.0,USA Today Prints Retraction on Vivus Qnexa (Qsymia) Approval Story,2012-07-17 14:26:00-04:00,VVUS,positive
1332486.0,Vivus Spokesperson Says No News of Qnexa FDA Approval Yet,2012-07-17 13:10:00-04:00,VVUS,positive
1332487.0,Rumors of FDA Approval of Qnexa Due Possibly to USA Today Article Mistakenly Published,2012-07-17 13:09:00-04:00,VVUS,positive
1332488.0,Hearing Unconfirmed of Vivus' Qnexa Approval,2012-07-17 13:04:00-04:00,VVUS,positive
1332489.0,"Vivus Filed Trademark QSYMIA as Brand Name for Qnexa on June 20, 2012",2012-07-17 12:45:00-04:00,VVUS,neutral
1332490.0,VIVUS Shares Spiking Lower on Possible Bear Raid,2012-07-17 09:42:00-04:00,VVUS,neutral
1332491.0,"Option Alert: Heavy Volume in Vivus July 26, 20 and 12 Puts Ahead of Tuesday's Qnexa PDUFA",2012-07-16 11:08:00-04:00,VVUS,positive
1332492.0,Vivus Spiking Higher Ahead of Tuesday's Qnexa PDUFA Date,2012-07-16 11:04:00-04:00,VVUS,neutral
1332493.0,Jefferies Comments on VIVUS' Qnexa Ahead of FDA Approval,2012-07-13 08:56:00-04:00,VVUS,positive
1332494.0,Vivus Spikes Lower,2012-07-12 09:50:00-04:00,VVUS,negative
1332495.0,Vivus Insiders Sell Ahead of FDA Qnexa Decision -Adam F,2012-07-09 10:24:00-04:00,VVUS,neutral
1332496.0,"Arena Pharmaceuticals Spikes Higher at Open, Vivus Spikes Lower",2012-07-06 09:31:00-04:00,VVUS,negative
1332497.0,These Are Four of the Hottest Biotechs in the Market Right Now,2012-07-05 13:19:00-04:00,VVUS,neutral
1332498.0,Top 4 Mid-Cap Stocks In The Biotechnology Industry With The Highest Cash,2012-07-02 02:10:00-04:00,VVUS,positive
1332499.0,Orexigen Therapeutics Falls 6% on Profit Taking,2012-06-29 15:13:00-04:00,VVUS,positive
1332500.0,"JP Morgan Maintains Vivus at Overweight, Raises PT from $30 to $35",2012-06-28 05:58:00-04:00,VVUS,neutral
1332501.0,4 Breakout Stocks To Watch Thursday,2012-06-27 18:35:00-04:00,VVUS,neutral
1332502.0,FDA Approves Arena's Lorcaserin,2012-06-27 14:55:00-04:00,VVUS,positive
1332503.0,"Arena Approval Boosts Biotech ETFs (ARNA, IBB, XBI)",2012-06-27 14:41:00-04:00,VVUS,positive
1332504.0,Orexigen Therapeutics Hits 52-Week Highs on Arena Approval,2012-06-27 13:17:00-04:00,VVUS,positive
1332505.0,Orexigen Therapeutics Crosses $5/Share on FDA Approval,2012-06-27 13:09:00-04:00,VVUS,positive
1332506.0,"Vivus, Orexigen Spike Higher on Arena Approval",2012-06-27 12:53:00-04:00,VVUS,positive
1332507.0,UPDATE: VIVUS: CHMP Schedules Oral Hearing On Qnexa Marketing Authorization For September,2012-06-05 06:48:00-04:00,VVUS,neutral
1332508.0,VIVUS Provides Update on Timing of European Decision for Qnexa(R) ,2012-06-05 06:45:00-04:00,VVUS,neutral
1332509.0,Vivus' Qnexa Is Not Guaranteed Approval. Remember Provenge?,2012-05-31 12:52:00-04:00,VVUS,negative
1332510.0,4 Smaller Alternatives to Big Pharma Obesity Treatments,2012-05-25 13:17:00-04:00,VVUS,neutral
1332511.0,"Option Alert: Vivus July 25/30 Call Spread; 5,325 Contracts; Currently $23.95",2012-05-22 15:59:00-04:00,VVUS,positive
1332512.0,Vivus Trading 2% Higher on Heavy Volume; Currently at $24.09,2012-05-22 09:46:00-04:00,VVUS,neutral
1332513.0,"Arena, Vivus, Orexigen are All Takeover Targets -Optionmonster",2012-05-11 12:39:00-04:00,VVUS,neutral
1332514.0,"Vivus, Orexigen Spiking Higher After-Hours Following Positive FDA Panel Vote on Arena Diet Drug",2012-05-10 16:43:00-04:00,VVUS,positive
1332515.0,Vivus Spiking Lower Ahead of FDA Panel Vote On Arena's Lorcaserin,2012-05-10 15:53:00-04:00,VVUS,negative
1332516.0,FDA in Online Webcast Making Comments About Problems of Obesity,2012-05-10 13:57:00-04:00,VVUS,negative
1332517.0,Vivus Reports Q1 EPS $-0.20 vs $-0.14 Est,2012-05-07 16:01:00-04:00,VVUS,neutral
1332518.0,CDC Says US Obesity Rate Will Increase to 42% of the US,2012-05-07 12:10:00-04:00,VVUS,positive
1332519.0,UPDATE: Vivus Announces FDA Approval Of STENDRA Tablets For The Treatment Of Erectile Dysfunction ,2012-04-27 15:42:00-04:00,VVUS,positive
1332520.0,Vivus Resumes Trading,2012-04-27 15:40:00-04:00,VVUS,neutral
1332521.0,PREVIEW: Vivus to Resume Trading at 3:40pm,2012-04-27 15:28:00-04:00,VVUS,neutral
1332522.0,Vivus Halted for Pending News,2012-04-27 13:22:00-04:00,VVUS,neutral
1332523.0,Vivus Halted; Pending News,2012-04-27 13:22:00-04:00,VVUS,neutral
1332524.0,Vivus Avanafil Competes with Viagra,2012-04-27 12:58:00-04:00,VVUS,neutral
1332525.0,Vivus Trading 3.2% Higher on Heavy Volume; Currently at $25.22,2012-04-27 12:50:00-04:00,VVUS,neutral
1332526.0,FDA Approves Vivus' Avanafil ,2012-04-27 12:48:00-04:00,VVUS,positive
1332527.0,"Vivus Spokesperson Says PDUFA for Avanafil Sunday April 29, Other Sources Reporting it for Friday April 27",2012-04-27 11:15:00-04:00,VVUS,neutral
1332528.0,"UPDATE: Credit Suisse Assumes Outperform, Cuts PT to $34 on Vivus; Qnexa REMS  ",2012-04-25 12:48:00-04:00,VVUS,positive
1332529.0,Vivus Trading 0.9% Higher on Heavy Volume; Currently at $21.87,2012-04-18 12:35:00-04:00,VVUS,neutral
1332530.0,Bank of America Reported a PDUFA Setback Giving Vivus Hope for REMS Approval,2012-04-10 10:05:00-04:00,VVUS,positive
1332531.0,"Morning Social Media Outlook for Monday April 10 (SFLY, VPHM, TSPT, MOH)",2012-04-10 10:03:00-04:00,VVUS,neutral
1332532.0,Vivus Rises 2.5% on Bank of America Raising PT to $30,2012-04-10 08:53:00-04:00,VVUS,neutral
1332533.0,UPDATE: Bank of America Raises Vivus' PT,2012-04-10 08:31:00-04:00,VVUS,neutral
1332534.0,Benzinga's Top Pre-Market Losers,2012-04-10 08:22:00-04:00,VVUS,negative
1332535.0,"Bank of America Maintains Vivus at Buy, Raises PO from $26 to $30",2012-04-10 07:16:00-04:00,VVUS,negative
1332536.0,"Bank of America Maintains Vivus at Buy, Raises PO from $26 to $30",2012-04-10 06:12:00-04:00,VVUS,negative
1332537.0,Vivus Falls 6% After-Hours on Extension of PDUFA Date for Qnexa ,2012-04-09 17:52:00-04:00,VVUS,neutral
1332538.0,UPDATE: VIVUS Qnexa PDUFA Date Extended,2012-04-09 16:47:00-04:00,VVUS,neutral
1332539.0,VIVUS Gets Notification from FDA; PDUFA Date for Qnexa Extended to July 17,2012-04-09 16:46:00-04:00,VVUS,neutral
1332540.0,Vivus Trading 4.3% Higher on Heavy Volume; Currently at $23.32,2012-04-05 09:35:00-04:00,VVUS,neutral
1332541.0,Vivus Spiking Higher on Heavy Volume; Currently at $22.27,2012-04-04 15:16:00-04:00,VVUS,neutral
1332542.0,"VVUS Analyst: Wouldn't Be Surprised GSK is Interested in Possible Acquisition, it is Clearly an Acquisition Target",2012-04-03 13:25:00-04:00,VVUS,positive
1332543.0,Glaxo SmithKline Spokesperson Says Company Does Not Comment on Speculation or Rumor with Regard to Chatter of Vivus Offer,2012-04-03 11:21:00-04:00,VVUS,neutral
1332544.0,Positive Rumors Circulate About Vivus,2012-04-03 10:31:00-04:00,VVUS,positive
1332545.0,Stocks Close Out Stellar Quarter on High Note; A Look at Top Performers,2012-03-30 15:56:00-04:00,VVUS,positive
1332546.0,Hearing Summer Street Positive on Vivus,2012-03-30 10:34:00-04:00,VVUS,positive
1332547.0,"Morning Social Media Outlook for Friday March 30 (IMGN, TIBX, XRTX, RIMM)",2012-03-30 10:22:00-04:00,VVUS,neutral
1332548.0,UPDATE: Jefferies Cuts Target to $9 on VIVUS,2012-03-30 09:44:00-04:00,VVUS,negative
1332549.0,Vivus Trading 5.2% Higher on Heavy Volume; Currently at $22.38,2012-03-30 09:38:00-04:00,VVUS,neutral
1332550.0,Hearing Wells Fargo Sees 3-Month PDUFA Delay for Vivus' Qnexa,2012-03-30 09:18:00-04:00,VVUS,negative
1332551.0,Benzinga's Top Pre-Market Gainers,2012-03-30 08:09:00-04:00,VVUS,positive
1332552.0,Benzinga's Top Upgrades,2012-03-30 07:53:00-04:00,VVUS,positive
1332553.0,"Financial Breakfast: Morning News Summary for March 30, 2012",2012-03-30 07:24:00-04:00,VVUS,neutral
1332554.0,UPDATE: Brean Murray Carret Upgrades VIVUS to Buy,2012-03-30 07:16:00-04:00,VVUS,neutral
1332555.0,"Jefferies & Company Maintains Vivus at Underperform, Lowers PT from $12 to $9",2012-03-30 07:05:00-04:00,VVUS,negative
1332556.0,FDA Spokesperson Says Unlikely That Discussion Over Past Couple of Days Will Impact Any Existing Applications -Adam F. Tweet,2012-03-30 06:53:00-04:00,VVUS,neutral
1332557.0,"Brean Murray Carret & Co. Upgrades Vivus from Hold to Buy, Announces PT of $30",2012-03-30 06:12:00-04:00,VVUS,neutral
1332558.0,US FDA Panel Votes 17-6 Obesity Drugs Without Initial Signal Of Cardiovascular Harm Should Still Be Required To Rule Out Excess Cardiovascular Risk With Clinical Trial Or Meta-Analysis -Reuters,2012-03-29 15:36:00-04:00,VVUS,negative
1332559.0,UPDATE: FDA Panel Currently Going On,2012-03-29 14:46:00-04:00,VVUS,neutral
1332560.0,Vivus Spiking Higher on Heavy Volume; Currently at $20.7,2012-03-29 14:41:00-04:00,VVUS,neutral
1332561.0,"Option Alert: Vivus April 31 Call; Block Trade, 6,488 Contracts",2012-03-29 11:44:00-04:00,VVUS,negative
1332562.0,Vivus Spiking Higher on Heavy Volume; Currently at $20.29,2012-03-29 09:34:00-04:00,VVUS,neutral
1332563.0,Vivus Trading 0.3% Lower on Heavy Volume; Currently at $21.24,2012-03-26 10:37:00-04:00,VVUS,negative
1332564.0,"Morning Social Media Outlook for Monday March 26 (LGF, A, H, YHOO)",2012-03-26 10:33:00-04:00,VVUS,neutral
1332565.0,Benzinga's Top Pre-Market Gainers,2012-03-26 08:08:00-04:00,VVUS,positive
1332566.0,A Peek Into The Market Before The Trading Starts,2012-03-26 07:24:00-04:00,VVUS,neutral
1332567.0,"Financial Breakfast: Morning News Summary for March 26, 2012",2012-03-26 07:22:00-04:00,VVUS,neutral
1332568.0,VIVUS Announces Acceptance of Avanafil Application in Europe ,2012-03-26 06:45:00-04:00,VVUS,positive
1332569.0,Vivus Spiking Higher,2012-03-23 12:41:00-04:00,VVUS,neutral
1332570.0,Top 4 Setups for Tuesday,2012-03-19 18:06:00-04:00,VVUS,positive
1332571.0,Vivus Spiking Highber,2012-03-19 09:45:00-04:00,VVUS,neutral
1332572.0,"Notable Performers Since the Turn of the Year (AAPL, VVUS, BAC)",2012-03-16 12:42:00-04:00,VVUS,neutral
1332573.0,Vivus Trading 2.7% Higher on Heavy Volume; Currently at $20.59,2012-03-15 13:08:00-04:00,VVUS,neutral
1332574.0,Vivus Trading 1.2% Lower on Heavy Volume; Currently at $20,2012-03-13 10:00:00-04:00,VVUS,negative
1332575.0,JP Morgan Still Positive on Qnexa for VIVUS,2012-03-06 11:55:00-05:00,VVUS,positive
1332576.0,Hearing JP Morgan Defending Vivus,2012-03-06 11:39:00-05:00,VVUS,positive
1332577.0,Benzinga's Top Pre-Market Losers,2012-03-06 08:18:00-05:00,VVUS,negative
1332578.0,"Arena Pharma Files for EMA Application, Hopes to Cure Weight Loss",2012-03-02 13:37:00-05:00,VVUS,positive
1332579.0,Vivus Spiking Higher on Heavy Volume; Currently at $22.52,2012-03-02 10:20:00-05:00,VVUS,neutral
1332580.0,Vivus Spiking Lower on Heavy Volume; Currently at $22.29,2012-03-01 13:56:00-05:00,VVUS,negative
1332581.0,Benzinga's Top Pre-Market Gainers,2012-03-01 08:15:00-05:00,VVUS,positive
1332582.0,A Peek Into The Market Before The Trading Starts,2012-03-01 07:41:00-05:00,VVUS,neutral
1332583.0,UPDATE: VIVUS Announces Pricing of 9M Share Offering of at $22.50,2012-03-01 07:14:00-05:00,VVUS,positive
1332584.0,Vivus Rises 4% on Pricing of Offering of 9M Shares at $22.50 Wednesday,2012-03-01 07:10:00-05:00,VVUS,positive
1332585.0,Vivus Rises 4% on Pricing of Offering,2012-02-29 18:12:00-05:00,VVUS,neutral
1332586.0,Vivus Prices 9M Shares at $22.50,2012-02-29 18:11:00-05:00,VVUS,positive
1332587.0,"Vivus Analyst: The FDA Has Crossed the Rubicon of Balancing Risk and Benefit, Understanding That Obesity is a Pandemic.  There Are Not a Lot of Products That Address Such Large Market Opportunities.  Vivus Will Not Give This Up Cheaply",2012-02-29 14:13:00-05:00,VVUS,positive
1332588.0,Vivus Spiking Higher on Chatter of Oversubscription,2012-02-29 13:49:00-05:00,VVUS,neutral
1332589.0,Hearing Chatter Vivus Offering Oversubscribed,2012-02-29 13:19:00-05:00,VVUS,neutral
1332590.0,Vivus Spiking Higher on Heavy Volume; Currently at $22.8,2012-02-29 13:18:00-05:00,VVUS,neutral
1332591.0,"Jefferies & Company Maintains Vivus at Underperform, Raises PT from $11 to $12",2012-02-29 07:01:00-05:00,VVUS,neutral
1332592.0,Vivus Q4 EPS $(0.14) vs $(0.11) Est,2012-02-28 17:16:00-05:00,VVUS,neutral
1332593.0,Vivus Proposes Offering of 8.5M Shares,2012-02-28 16:39:00-05:00,VVUS,positive
1332594.0,Vivus CEO Wilson Sells 50K Shares -Form 4,2012-02-28 14:55:00-05:00,VVUS,positive
1332595.0,Vivus Trading 5% Lower on Heavy Volume; Currently at $22.6,2012-02-28 09:49:00-05:00,VVUS,negative
1332596.0,Vivus Spiking Lower,2012-02-28 09:44:00-05:00,VVUS,negative
1332597.0,Vivus Trending On Social Media,2012-02-27 15:23:00-05:00,VVUS,neutral
1332598.0,Vivus CEO: Looking for Partner Outside of US,2012-02-27 12:33:00-05:00,VVUS,neutral
1332599.0,Vivus CEO: 'Expect Qnexa Approval in April',2012-02-27 12:32:00-05:00,VVUS,positive
1332600.0,PREVIEW: Vivus CEO to Appear on CNBC,2012-02-27 12:29:00-05:00,VVUS,neutral
1332601.0,"Option Alert: Vivus April 30 Call; Block Trade, 3,844 Contracts",2012-02-27 10:24:00-05:00,VVUS,negative
1332602.0,Vivus Trading 8% Higher on Heavy Volume; Currently at $23.89,2012-02-27 09:38:00-05:00,VVUS,neutral
1332603.0,Benzinga's Top Pre-Market Gainers,2012-02-27 08:32:00-05:00,VVUS,positive
1332604.0,Vivus Spiking Higher Pre-Market,2012-02-27 08:19:00-05:00,VVUS,neutral
1332605.0,Vivus Strength May Be Attributable to Comments From Passport Capital's John Burbank,2012-02-24 14:07:00-05:00,VVUS,positive
1332606.0,Intra-Day Trading Update: Vivus Showing Significant Strength,2012-02-24 13:57:00-05:00,VVUS,positive
1332607.0,Vivus Trading 12.2% Higher on Heavy Volume; Currently at $21.02,2012-02-24 13:38:00-05:00,VVUS,neutral
1332608.0,Vivus Trading 8.9% Higher on Heavy Volume; Currently at $20.4,2012-02-24 12:54:00-05:00,VVUS,neutral
1332609.0,"Morning Social Media Outlook for Friday Feb 24 (DDD, FXEN, CRM, MAR)",2012-02-24 11:04:00-05:00,VVUS,neutral
1332610.0,Vivus Analyst: DCF Model Assumes Fair Value of $23.35/Share,2012-02-24 09:53:00-05:00,VVUS,positive
1332611.0,Biopharmaceutical Stock to Watch: VIVUS Massive Move on FDA Approval of Qnexa®,2012-02-23 16:00:00-05:00,VVUS,positive
1332612.0,"U.S. Obesity Spells Opportunity for VVUS, OREX and ARNA",2012-02-23 14:25:00-05:00,VVUS,positive
1332613.0,Vivus Falling to Lows,2012-02-23 14:24:00-05:00,VVUS,negative
1332614.0,"Option Alert: Vivus January 2013 25 Call; Block Trade, 4,900 Contracts",2012-02-23 14:23:00-05:00,VVUS,negative
1332615.0,Vivus Investors Rejoice as Weight Loss Drug Receives Positive Panel Vote,2012-02-23 13:26:00-05:00,VVUS,positive
1332616.0,PREVIEW: Vivus CEO Leland F. Wilson to Appear on CNBC Fast Money Halftime Report on Monday February 27,2012-02-23 12:05:00-05:00,VVUS,neutral
1332617.0,"Morning Social Media Outlook for Thursday Feb 23 (VVUS, INTU, DELL, HPQ)",2012-02-23 11:23:00-05:00,VVUS,neutral
1332618.0,UPDATE: Bank of England Raises Price Target on Vivus to $22,2012-02-23 11:11:00-05:00,VVUS,neutral
1332619.0,UPDATE: Brean Murray Carret Upgrades Vivus to Hold,2012-02-23 10:48:00-05:00,VVUS,neutral
1332620.0,UPDATE: Rodman & Renshaw Upgrades Vivus to Outperform,2012-02-23 10:42:00-05:00,VVUS,neutral
1332621.0,Vivus Up 100% After Receiving Positive Panel Vote for Qnexa,2012-02-23 09:33:00-05:00,VVUS,positive
1332622.0,"Rodman & Renshaw Upgrades Vivus from Market Perform to Market Outperform, Maintains PT at $39",2012-02-23 09:09:00-05:00,VVUS,neutral
1332623.0,Benzinga's Top Pre-Market Gainers,2012-02-23 08:34:00-05:00,VVUS,positive
1332624.0,Benzinga's Top Upgrades,2012-02-23 07:41:00-05:00,VVUS,positive
1332625.0,A Peek Into The Market Before The Trading Starts,2012-02-23 07:34:00-05:00,VVUS,neutral
1332626.0,"JP Morgan Maintains Vivus at Overweight, Raises PT from $13 to $30",2012-02-23 07:26:00-05:00,VVUS,neutral
1332627.0,UPDATE: JP Morgan Raises PT on VIVUS to $30,2012-02-23 07:26:00-05:00,VVUS,positive
1332628.0,"Bank of America Maintains Vivus at Buy, Raises PO from $16 to $22",2012-02-23 06:40:00-05:00,VVUS,negative
1332629.0,"Brean Murray Carret & Co. Upgrades Vivus from Sell to Hold, Removes PT from $2 to $",2012-02-23 06:28:00-05:00,VVUS,neutral
1332630.0,"Viva Vivus, But Not In ETFs (VVUS, IBB, PJP)",2012-02-23 00:05:00-05:00,VVUS,neutral
1332631.0,UPDATE: Vivus Rises 100% on Positive FDA Panel Vote on Qnexa,2012-02-22 18:29:00-05:00,VVUS,positive
1332632.0,Arena Pharmaceuticals Rises 19% on Positive FDA Panel Vote on Vivus' Qnexa,2012-02-22 17:52:00-05:00,VVUS,positive
1332633.0,Vivus Crosses $20,2012-02-22 17:50:00-05:00,VVUS,neutral
1332634.0,Vivus Rises 88% on Positive FDA Vote,2012-02-22 17:50:00-05:00,VVUS,positive
1332635.0,"Vivus Resumes Trading, Currently Around $19 on Positive FDA Panel Vote on Qnexa",2012-02-22 17:48:00-05:00,VVUS,positive
1332636.0,Vivus Resumes Trading,2012-02-22 17:45:00-05:00,VVUS,neutral
1332637.0,PREVIEW: Vivus to Resume Trading at 5:45pm,2012-02-22 17:35:00-05:00,VVUS,neutral
1332638.0,Arena Pharmaceuticals Rises 10% on Positive FDA Panel Vote on Vivus' Qnexa,2012-02-22 17:11:00-05:00,VVUS,positive
1332639.0,Orexigen Therapeutics and Arena Pharmaceuticals Soar On Positive Qnexa Panel Vote,2012-02-22 17:07:00-05:00,VVUS,positive
1332640.0,FDA Panel Votes 20-2 In Favor of Approval For Vivus' Qnexa,2012-02-22 16:31:00-05:00,VVUS,positive
1332641.0,Weight Watchers Falls on FDA Panel Vote on Vivus' Qnexa,2012-02-22 16:26:00-05:00,VVUS,neutral
1332642.0,Weight Watchers Falling a Bit after Vivus Weight-Loss Drug Receives Positive Vote,2012-02-22 16:25:00-05:00,VVUS,positive
1332643.0,"Vivus Receives Positive Vote for Qnexa, 20-2",2012-02-22 16:21:00-05:00,VVUS,positive
1332644.0,"FDA Panel Votes  20  Yes, 2 No  in Favor of Vivus' Qnexa",2012-02-22 16:21:00-05:00,VVUS,positive
1332645.0,"Orexigen Therapeutics, Arena Pharmaceuticals Spike Higher as FDA Panels Prepares to Vote on Vivus' Qnexa",2012-02-22 15:39:00-05:00,VVUS,neutral
1332646.0,"Vivus: Only 1 Death in Trials, In Placebo Patient",2012-02-22 10:00:00-05:00,VVUS,negative
1332647.0,Vivus: 70% to 75% of Patients Lost Greater Than 5% of Body Weight,2012-02-22 09:40:00-05:00,VVUS,positive
1332648.0,"Vivus FDA Panel: Qnexa Reduces Blood Pressure, Shows Meaningful Clinical Weight Loss; Still Under Review",2012-02-22 09:31:00-05:00,VVUS,negative
1332649.0,Vivus: Reducing Obesity and Preventing Diabetes Decreases Birth Defects,2012-02-22 09:26:00-05:00,VVUS,negative
1332650.0,Vivus: Qnexa Lowers Heart Rate Over One Year in Patients with High Heart Rate,2012-02-22 08:57:00-05:00,VVUS,negative
1332651.0,Vivus Presentation to FDA Panel Begins,2012-02-22 08:17:00-05:00,VVUS,neutral
1332652.0,Vivus Halted for FDA Panel,2012-02-22 07:01:00-05:00,VVUS,neutral
1332653.0,Benzinga's Volume Losers,2012-02-21 14:52:00-05:00,VVUS,negative
1332654.0,Vivus Spikes Lower on Negative Street Article,2012-02-21 11:32:00-05:00,VVUS,negative
1332655.0,"A Negative Vote for Vivus Obesity Drug, Says 'FDA Panel Whisperer' -TheStreet",2012-02-21 11:31:00-05:00,VVUS,negative
1332656.0,Vivus Spiking Lower,2012-02-21 11:30:00-05:00,VVUS,negative
1332657.0,Vivus Analyst: Membership on FDA Panel is Negatively Biased.  Five Members Previously Voted Against an Obesity Drug; Four Have Voted in Favor.,2012-02-17 12:02:00-05:00,VVUS,positive
1332658.0,Notable Put Options Activity in VIVUS,2012-02-17 10:20:00-05:00,VVUS,neutral
1332659.0,"Option Alert: Vivus February 11 Put; Block Trade, 4,802 Contracts",2012-02-17 09:53:00-05:00,VVUS,negative
1332660.0,Vivus Hoping Weight Loss Drug Will Gain Approval as FDA Releases Briefing Documents,2012-02-17 09:39:00-05:00,VVUS,positive
1332661.0,FDA Staff Say Qnexa Can Cause Too Much Acid in Body Fluids and Long-Term Effects of This on Overweight and Obese Patients Are Unknown -Reuters ,2012-02-17 08:15:00-05:00,VVUS,negative
1332662.0,FDA Staff Say Qnexa Ingredient Topiramate Is Linked to Cognitive-Related Side Effects Like Confusion and Difficulty with Attention -Reuters ,2012-02-17 08:12:00-05:00,VVUS,negative
1332663.0,"Adam Feuerstein: Vivus FDA Briefing Docs Look Like Just the Facts, No Big Conclusions ",2012-02-17 08:11:00-05:00,VVUS,positive
1332664.0,UPDATE: FDA Will Ask Panel Whether A CV Study Will Be Required Prior to Vivus Qnexa Approval,2012-02-17 08:09:00-05:00,VVUS,positive
1332665.0,Vivus Releases Positive Briefing Documents; Stock Up 7%,2012-02-17 08:04:00-05:00,VVUS,positive
1332666.0,Hearing Leerink Does Not View Janet Woodcock's Comments as Negative for Vivus,2012-02-16 15:34:00-05:00,VVUS,negative
1332667.0,Vivus May be Reacting to Comments Made by FDA's Janet Woodcock at Leerink Swann Conference. Trying to Confirm,2012-02-16 15:12:00-05:00,VVUS,neutral
1332668.0,Vivus Analyst: The FDA Will Likely Require a Large Cardiovascular Safety Study of Qnexa Before Approval.  Safety Issue of Birth Defects is Secondary to Heart Defect Issue.  ,2012-02-16 15:03:00-05:00,VVUS,positive
1332669.0,No FDA Briefing Documents on Vivus Yet,2012-02-16 15:02:00-05:00,VVUS,negative
1332670.0,Vivus Spiking Lower on Heavy Volume; Currently at $11.76,2012-02-16 15:01:00-05:00,VVUS,negative
1332671.0,Vivus Spiking Lower on Heavy Volume; Currently at $11.58,2012-02-16 14:59:00-05:00,VVUS,negative
1332672.0,Vivus Trading 7.6% Higher on Heavy Volume; Currently at $12.91,2012-02-16 14:11:00-05:00,VVUS,neutral
1332673.0,"Option Alert: Vivus June 20 Call; Block Trade, 2,700 Contracts",2012-02-16 11:47:00-05:00,VVUS,negative
1332674.0,Hearing Positive Chatter on Vivus Regarding Upcoming FDA Panel,2012-02-13 13:49:00-05:00,VVUS,positive
1332675.0,Positive Rumors Circulate About Vivus,2012-02-13 13:44:00-05:00,VVUS,positive
1332676.0,"Option Alert: Vivus June 5 Put; 2,450 Contracts",2012-02-13 11:53:00-05:00,VVUS,positive
1332677.0,"Option Alert: Vivus March 15 Call; Block Trade, 3,388 Contracts",2012-02-08 15:48:00-05:00,VVUS,negative
1332678.0,Vivus Hits 52-Week High of $12.86,2012-02-07 09:31:00-05:00,VVUS,neutral
1332679.0,"VIVUS: Feb. 22 Date for FDA Advisory Panel of its Obesity Drug, Qnexa",2012-01-30 10:21:00-05:00,VVUS,neutral
1332680.0,"Option Alert: Vivus February 12 Call; Block Trade, 3,772 Contracts",2012-01-18 14:33:00-05:00,VVUS,negative
1332681.0,VIVUS Announces REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function ,2012-01-17 06:47:00-05:00,VVUS,positive
1332682.0,Vivus Hits 52-Week High of $12.16,2012-01-12 09:30:00-05:00,VVUS,neutral
1332683.0,Vivus Hits 52-Week High of $12.01,2012-01-11 09:42:00-05:00,VVUS,neutral
1332684.0,"Jefferies Maintains Underperform, $3 PT on VIVUS",2012-01-10 07:34:00-05:00,VVUS,neutral
1332685.0,"Rodman & Renshaw Reiterates Perform, $10-$11 PT on VVUS",2012-01-10 06:36:00-05:00,VVUS,neutral
1332686.0,Vivus Hits 52-Week High of $11.67,2012-01-09 09:31:00-05:00,VVUS,neutral
1332687.0,Benzinga's Top Pre-Market Gainers,2012-01-09 08:10:00-05:00,VVUS,positive
1332688.0,VIVUS Provides Qnexa Regulatory Update; FDA Requests Removal of Contraindication for Women of Childbearing Potential  ,2012-01-09 06:45:00-05:00,VVUS,neutral
1332689.0,Rodman & Renshaw Initiates VIVUS at Market Perform,2012-01-05 07:39:00-05:00,VVUS,neutral
1332690.0,VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity ,2011-12-23 06:47:00-05:00,VVUS,neutral
1332691.0,"End-of-Day Market Summary for December 22, 2011",2011-12-22 16:16:00-05:00,VVUS,neutral
1332692.0,Afternoon Movers; Markets Moved Higher,2011-12-22 16:05:00-05:00,VVUS,neutral
1332693.0,Leerink Swann Downgrades VIVUS to Market Perform,2011-12-22 09:24:00-05:00,VVUS,neutral
1332694.0,Benzinga's Top Pre-Market Losers,2011-12-22 08:17:00-05:00,VVUS,negative
1332695.0,Benzinga's Top Downgrades,2011-12-22 07:31:00-05:00,VVUS,positive
1332696.0,Roth Capital Downgrades VIVUS to Neutral,2011-12-22 07:17:00-05:00,VVUS,neutral
1332697.0,VIVUS Reports Topline Findings From FORTRESS ,2011-12-21 16:00:00-05:00,VVUS,neutral
1332698.0,UPDATE: Bank of America Raises Price Target on Vivus to $14,2011-12-08 07:44:00-05:00,VVUS,neutral
1332699.0,Bank of America Raises Po on Vivus to $14,2011-12-08 06:26:00-05:00,VVUS,negative
1332700.0,Biotech Stocks On the Move,2011-12-05 17:26:00-05:00,VVUS,neutral
1332701.0,"Jefferies Maintains Underperform, $3 Target on VIVUS ",2011-12-05 08:36:00-05:00,VVUS,neutral
1332702.0,Vivus Reports Q3 EPS $(0.10) vs $(0.13) Est,2011-11-07 16:01:00-05:00,VVUS,neutral
1332703.0,Credit Suisse Initiating Coverage on Vivus,2011-11-04 09:35:00-04:00,VVUS,positive
1332704.0,Qnexa Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment ,2011-11-03 17:01:00-04:00,VVUS,negative
1332705.0,VIVUS Announces FDA Accepts New Drug Application Filing for Qnexa ,2011-11-03 12:15:00-04:00,VVUS,positive
1332706.0,Vivus Hopes FDA Approval Will Lead to Fat Profits,2011-10-21 10:45:00-04:00,VVUS,positive
1332707.0,VIVUS Resubmits Qnexa NDA to the FDA ,2011-10-17 06:45:00-04:00,VVUS,neutral
1332708.0,Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss,2011-10-03 08:46:00-04:00,VVUS,positive
1332709.0,VIVUS: 10% Weight Loss Could Save Medicare $35 Billion ,2011-09-22 07:37:00-04:00,VVUS,positive
1332710.0,UPDATE: Vivus and Arena Pharmaceuticals Spike Higher on Orexigen Therapeutics News,2011-09-20 16:04:00-04:00,VVUS,neutral
1332711.0,"McNicoll, Lewis & Vlak Reiterates Vivus Buy, $16 PT",2011-09-16 13:32:00-04:00,VVUS,neutral
1332712.0,Notable Call Options Activity in VIVUS,2011-09-15 10:54:00-04:00,VVUS,neutral
1332713.0,Pre-Market Movers; Netflix Down 15%,2011-09-15 09:22:00-04:00,VVUS,neutral
1332714.0,VIVUS Announces Agreement Reached with FDA to Re-Submit QNEXA NDA Prior to Completion of FORTRESS ,2011-09-15 06:45:00-04:00,VVUS,positive
1332715.0,"Financial Breakfast: Morning News Summary for September 13, 2011",2011-09-13 07:47:00-04:00,VVUS,neutral
1332716.0,A Peek Into The Market Before The Trading Starts,2011-09-13 07:31:00-04:00,VVUS,neutral
1332717.0,VIVUS Announces Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting ,2011-09-13 06:46:00-04:00,VVUS,positive
1332718.0,Tuesday's NASDAQ Top Gainers,2011-09-07 12:37:00-04:00,VVUS,positive
1332719.0,VVUS Announces FDA Acceptance of Avanafil NDA,2011-09-01 16:03:00-04:00,VVUS,positive
1332720.0,VIVUS Announces FDA Acceptance of Avanafil ,2011-09-01 16:02:00-04:00,VVUS,positive
1332721.0,Vivus Spiking Higher on Heavy Volume,2011-09-01 16:01:00-04:00,VVUS,neutral
1332722.0,UPDATE: VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock at $6.65/Share,2011-08-23 09:43:00-04:00,VVUS,neutral
1332723.0,UPDATE: Vivus In $45.8M Registered Direct Offering Of Common Stock; Hearing at $6.65/Share,2011-08-23 09:41:00-04:00,VVUS,neutral
1332724.0,Vivus In $45.8M Registered Direct Offering Of Common Stock,2011-08-23 09:38:00-04:00,VVUS,neutral
1332725.0,VIVUS Announces Study Showing Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life  ,2011-08-05 07:33:00-04:00,VVUS,positive
1332726.0,"McNicoll, Lewis & Vlak Reiterates Vivus Buy, $16 PT",2011-08-03 13:37:00-04:00,VVUS,neutral
1332727.0,Earnings Scheduled For August 1,2011-08-01 03:31:00-04:00,VVUS,neutral
1332728.0,How to Profit from Exploding Government Healthcare Costs ,2011-07-28 09:37:00-04:00,VVUS,positive
1332729.0,Fifteen Health Care ETFs Trading Near 52-Week Highs,2011-07-21 13:57:00-04:00,VVUS,positive
1332730.0,Twelve Health Care ETFs Trading Near 52-Week Highs,2011-07-13 07:38:00-04:00,VVUS,positive
1332731.0,Biotech/Pharma Stocks Investor News Alert,2011-07-06 10:52:00-04:00,VVUS,positive
1332732.0,A Peek Into The Market Before The Trading Starts,2011-06-30 07:27:00-04:00,VVUS,neutral
1332733.0,VIVUS Submits New Drug Application for Avanafil ,2011-06-30 06:58:00-04:00,VVUS,neutral
1332734.0,VIVUS Announces Multiple Presentations Featuring Long-term QNEXA Data at the American Diabetes Association 71st Scientific Sessions ,2011-06-22 07:00:00-04:00,VVUS,neutral
1332735.0,A Peek Into The Market Before The Trading Starts,2011-06-17 07:23:00-04:00,VVUS,neutral
1332736.0,VIVUS Announces Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting ,2011-06-17 07:00:00-04:00,VVUS,negative
1332737.0,Benzinga's Top Pre-Market NASDAQ Losers,2011-06-03 08:17:00-04:00,VVUS,negative
1332738.0,VIVUS Announces Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity,2011-05-31 11:06:00-04:00,VVUS,neutral
1332739.0,MLV Reiterates Buy Rating On Vivus,2011-05-25 08:29:00-04:00,VVUS,neutral
1332740.0,Benzinga's Top Pre-Market NASDAQ Gainers,2011-05-25 08:10:00-04:00,VVUS,positive
1332741.0,A Peek Into The Market Before The Trading Starts,2011-05-25 07:27:00-04:00,VVUS,neutral
1332742.0,"VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients, Met All Primary Endpoints",2011-05-25 07:09:00-04:00,VVUS,positive
1332743.0,VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients ,2011-05-25 07:09:00-04:00,VVUS,positive
1332744.0,Vivus Trades Higher on Bloomberg Article ,2011-05-18 07:40:00-04:00,VVUS,neutral
1332745.0,Arena Pharma Rallies in Sympathy with Vivus Phase 3 Results,2011-05-17 12:31:00-04:00,VVUS,positive
1332746.0,VIVUS Announces Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting,2011-05-17 12:31:00-04:00,VVUS,positive
1332747.0,"Benzinga's Top Pre-Market NASDAQ Gainers (KLIC, VVUS, ASML, ASMI)",2011-05-03 08:14:00-04:00,VVUS,positive
1332748.0,Jefferies Comments On VIVUS Safety Analysis,2011-05-03 07:36:00-04:00,VVUS,positive
1332749.0,"Pre-Market Top Percentage Gainers and Losers (GLBC, LVLT, AMMD, ENDP, RAME, VVUS, BIIB, QUIK, MDVN, JACK, EDMC, GS, SINA)",2011-04-11 09:08:00-04:00,VVUS,negative
1332750.0,Commodities Up on Strength of Emerging Markets  04-04-2011,2011-04-04 19:32:00-04:00,VVUS,positive
1332751.0,"Orexigen And Vivus Surge On Blood Pressure Data (OREX, VVUS)",2011-04-04 13:06:00-04:00,VVUS,negative
1332752.0,"Morning Trade: Top And Bottom Five Percentage Gainers (MSSR, OREX, TFCO, VVUS, CSCD, AMIE, DGW, AFFM, RVSN, IBCPO)",2011-04-04 11:23:00-04:00,VVUS,positive
1332753.0,Vivus At Highs Of The Session (VUVS),2011-04-04 10:25:00-04:00,VVUS,neutral
1332754.0,"Morning Market Movers (MSSR, ZNWAW, TFCO, VVUS)",2011-04-04 09:52:00-04:00,VVUS,neutral
1332755.0,"Benzinga's Top Pre-Market NASDAQ Gainers (VVUS, OREX, CIGX, TEVA)",2011-04-04 08:21:00-04:00,VVUS,positive
1332756.0,"Options Brief: VIVUS, Inc. (VVUS)",2011-03-28 12:11:00-04:00,VVUS,neutral
1332757.0,Running Late  03-04-2011,2011-03-04 15:43:00-05:00,VVUS,neutral
1332758.0," How To Trade Biotech Stocks Better: Trading The NDAs (BIIB, AMGN, VVUS, GENZ, GLD)",2011-03-04 11:37:00-05:00,VVUS,positive
1332759.0,Puts Active as VIVUS Plunges (VVUS),2011-03-04 09:58:00-05:00,VVUS,positive
1332760.0,Vivus Ticks Lower On FDA Caution (VVUS),2011-03-04 09:46:00-05:00,VVUS,negative
1332761.0,"Fast Money Pops & Drops, March 1st (CCL, BYD, LO, EMN, VVUS)",2011-03-01 20:41:00-05:00,VVUS,neutral
1332762.0, Vivus Reports EPS of $(0.19) vs. $(0.22),2011-02-28 16:01:00-05:00,VVUS,neutral
1332763.0,Setback for Orexigen - Analyst Blog,2011-02-02 09:52:00-05:00,VVUS,neutral
1332764.0,Setback for Orexigen - Analyst Blog,2011-02-02 09:30:00-05:00,VVUS,neutral
1332765.0,What's Hot on TheStreet,2011-02-01 12:35:00-05:00,VVUS,neutral
1332766.0,VIVUS Trading Significantly Lower Today (VVUS),2011-02-01 09:36:00-05:00,VVUS,negative
1332767.0,"Benzinga's Top Pre-Market NASDAQ Losers (OREX, VVUS, CCME, DEPO)",2011-02-01 08:30:00-05:00,VVUS,negative
1332768.0,"Trading Orexigen Therapeutics Terrible Results (OREX, ARNA, VVUS)",2011-02-01 08:26:00-05:00,VVUS,negative
1332769.0,"Trading Orexigen's FDA Rejection (VVUS, OREX)",2011-02-01 07:44:00-05:00,VVUS,negative
1332770.0,"Benzinga's Top Pre-Market NASDAQ Losers (ACOR, VVUS, SYNA, MNKD)",2011-01-21 08:35:00-05:00,VVUS,negative
1332771.0,"3 Stocks For New Year's Diets (ARNA, VVUS, OREX) ",2010-12-30 11:25:00-05:00,VVUS,neutral
1332772.0,Vivus Seeks EU Nod for Qnexa - Analyst Blog,2010-12-27 09:30:00-05:00,VVUS,neutral
1332773.0,Vivus Seeks EU Nod for Qnexa - Analyst Blog,2010-12-27 08:45:00-05:00,VVUS,neutral
1332774.0,"Arena: Long, Hard 'Path' to Obesity Drug Approval",2010-12-22 13:05:00-05:00,VVUS,positive
1332775.0,Vivus Files Application For Weight Loss Drug (VVUS),2010-12-20 09:43:00-05:00,VVUS,negative
1332776.0,"Benzinga's Top Pre-Market NASDAQ Losers (OXPS, VVUS, NGPC, LOGI)",2010-12-14 08:51:00-05:00,VVUS,negative
1332777.0,"VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting (VVUS)",2010-12-14 07:53:00-05:00,VVUS,neutral
1332778.0,VIVUS Up Pre-Market ,2010-12-13 08:38:00-05:00,VVUS,neutral
1332779.0,Biotech Sector Weekly Rewind,2010-12-11 08:10:00-05:00,VVUS,neutral
1332780.0,Jefferies Comments On New FDA Insight On Obesity Drugs,2010-12-10 07:56:00-05:00,VVUS,neutral
1332781.0,Biotech Stock Mailbag: Orexigen and Vivus,2010-12-10 07:00:00-05:00,VVUS,neutral
1332782.0,ED Drug Could Support Vivus - Analyst Blog,2010-12-09 12:18:00-05:00,VVUS,positive
1332783.0,ED Drug Could Support Vivus - Analyst Blog,2010-12-09 11:48:00-05:00,VVUS,positive
1332784.0,Orexigen Therapeutics Dropping After Monster Gain Yesterday,2010-12-09 10:02:00-05:00,VVUS,positive
1332785.0,FDA Panel Backs OREX's Contrave  - Analyst Blog,2010-12-08 16:03:00-05:00,VVUS,negative
1332786.0,FDA Panel Backs OREX's Contrave  - Analyst Blog,2010-12-08 15:42:00-05:00,VVUS,negative
1332787.0,Biotechnology Stocks Hot Off Of Orexigen Panel Vote,2010-12-08 13:01:00-05:00,VVUS,neutral
1332788.0,Orexigen Therapeutics Off Highs (OREX),2010-12-08 12:47:00-05:00,VVUS,neutral
1332789.0,"Options Brief: VIVUS, Inc. (VVUS)",2010-12-08 10:39:00-05:00,VVUS,neutral
1332790.0,"Morning Market Movers (OREX, FCEC, VVUS, ARNA)",2010-12-08 10:03:00-05:00,VVUS,neutral
1332791.0,Vivus Continues Gains Pre-Market on FDA Panel Approval (VVUS),2010-12-08 08:35:00-05:00,VVUS,positive
1332792.0,Orexigen Up On FDA Vote,2010-12-08 08:32:00-05:00,VVUS,neutral
1332793.0,"Benzinga's Top Pre-Market NASDAQ Gainers (OREX, VVUS, RYAAY, AAPL)",2010-12-08 08:19:00-05:00,VVUS,positive
1332794.0,"Men's Wearhouse, Orexigen: After-Hours Trading",2010-12-07 19:21:00-05:00,VVUS,neutral
1332795.0,FDA Panel Approves Orexigen Diet Drug Contrave,2010-12-07 17:28:00-05:00,VVUS,positive
1332796.0,"What Diet Pill Stocks To Trade Alongside Orexigen Therapeutics (OREX, ARNA, VVUS)",2010-12-07 16:47:00-05:00,VVUS,neutral
1332797.0,Vivus Skyrocketing On Vote (VVUS),2010-12-07 15:54:00-05:00,VVUS,neutral
1332798.0,VIVUS Spiking to New Session Highs (VVUS),2010-12-07 15:51:00-05:00,VVUS,neutral
1332799.0,Orexigen Therapeutics: FDA Panel Live Blog,2010-12-07 07:47:00-05:00,VVUS,neutral
1332800.0,"Benzinga's Top Pre-Market NASDAQ Gainers (VRGY, RDWR, NVMI, VVUS)",2010-12-06 08:47:00-05:00,VVUS,positive
1332801.0,Orexigen: Predicting Tuesday's FDA Panel,2010-12-03 10:35:00-05:00,VVUS,neutral
1332802.0,"Benzinga's After Hours Gainers (PSS, FNSR, VVUS)",2010-12-01 18:25:00-05:00,VVUS,neutral
1332803.0,Orexigen: Contrave FDA Panel Preview,2010-11-30 07:57:00-05:00,VVUS,neutral
1332804.0,VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results: Loss Per Share of $0.20,2010-11-08 16:04:00-05:00,VVUS,neutral
1332805.0,"Mad Money Lightning Round OT: Cramer Thinks That MU Should Be Sold (MU, AMD, CY, VVUS, CAAS, F)",2010-11-07 15:19:00-05:00,VVUS,negative
1332806.0,Biotech Stock Mailbag: Orexigen ,2010-11-05 11:12:00-04:00,VVUS,neutral
1332807.0,"Benzinga's Top Pre-Market NASDAQ Losers (VVUS, RYAAY, PTNR, VOD)",2010-11-01 08:49:00-04:00,VVUS,negative
1332808.0,Jefferies Remains Cautious On Vivus Pending Qnexa Approval,2010-11-01 08:30:00-04:00,VVUS,positive
1332809.0,VIX on the Move Up  10-29-2010,2010-10-29 14:46:00-04:00,VVUS,neutral
1332810.0,"Friday's Mid-Day Options Volume Leaders (MSFT, BAC, VVUS, AAPL, AA)",2010-10-29 11:30:00-04:00,VVUS,neutral
1332811.0,"Mid-Day Market Movers (IIIIU, FMR, VVUS, MWW)",2010-10-29 10:36:00-04:00,VVUS,neutral
1332812.0,"Company News for October 29, 2010 - Corporate Summary",2010-10-29 10:03:00-04:00,VVUS,neutral
1332813.0,"Benzinga's Top Pre-Market NASDAQ Gainers (VVUS, PWER, CSTR, MIPS)",2010-10-29 08:20:00-04:00,VVUS,positive
1332814.0,J.P. Morgan Upgrades Vivus (VVUS),2010-10-29 07:31:00-04:00,VVUS,neutral
1332815.0,JP Morgan Upgrades VVUS To Overweight,2010-10-29 06:56:00-04:00,VVUS,neutral
1332816.0,"Market Listless, Waiting on Elections & Fed",2010-10-28 18:19:00-04:00,VVUS,neutral
1332817.0,Market Watchers See QE Priced Into Market  10-19-2010,2010-10-19 15:19:00-04:00,VVUS,neutral
1332818.0,Vivus Sells MUSE to Meda - Analyst Blog,2010-10-18 02:33:00-04:00,VVUS,neutral
1332819.0,"Biotech Stocks to Watch for Monday; (OTCBB: UVFT), (AMEX: PIP), (NASDAQ:VVUS), (NASDAQ: AMGN)",2010-10-17 23:54:00-04:00,VVUS,neutral
1332820.0,Readers Pick Drug Approval Winners & Losers,2010-10-04 07:15:00-04:00,VVUS,positive
1332821.0,"Benzinga's Top Pre-Market NASDAQ Gainers (SEED, VVUS, PWER, RDWR) ",2010-09-22 08:59:00-04:00,VVUS,positive
1332822.0,"Benzinga's Top Upgrades (NMR, WSO, VVUS, ENR)",2010-09-22 08:15:00-04:00,VVUS,positive
1332823.0,Waiting on the Fed  09-21-2010,2010-09-21 15:05:00-04:00,VVUS,neutral
1332824.0,Vivus Soaring On Qnexa Data (VVUS),2010-09-21 10:11:00-04:00,VVUS,neutral
1332825.0,"Benzinga's Top Pre-Market NASDAQ Gainers (TTPA, VVUS, AAWW, BPHX)",2010-09-21 09:37:00-04:00,VVUS,positive
1332826.0,"Benzinga's Top Pre-Market NASDAQ Losers (ARNA, OREX, ACFN, VVUS)",2010-09-17 09:21:00-04:00,VVUS,negative
1332827.0,More Unconfirmed Chatter On Vivus Takeover (VVUS),2010-09-10 11:01:00-04:00,VVUS,negative
1332828.0,VVUS) Unconfirmed rumor that (LLY) will buy the company for  $9.00 Cash,2010-08-26 09:45:00-04:00,VVUS,negative
1332829.0,"Benzinga's After Hours Movers (HBC, PBR, GRMN, JDSU, VVUS, CECO, GES, THC)",2010-08-25 18:12:00-04:00,VVUS,neutral
1332830.0,Vivus Loss Widens  - Analyst Blog,2010-08-05 15:40:00-04:00,VVUS,negative
1332831.0,Vivus’s (VVUS) Future Dependent On Qnexa ,2010-08-03 13:29:00-04:00,VVUS,neutral
1332832.0,"Wells Fargo Lowering Earnings Estimates (CWT, EGN, HK, SM, PFG,  DVA, HLS, VVUS, SNH)",2010-08-03 09:04:00-04:00,VVUS,neutral
1332833.0,VIVUS Misses Estimates; Provides Qnexa Update (VVUS),2010-08-02 16:13:00-04:00,VVUS,negative
1332834.0,Bears Grab Control on Heavier Volume  07-16-2010,2010-07-16 15:12:00-04:00,VVUS,neutral
1332835.0,"Vivus Tumbles 70% on FDA Disapproval; Piper Jaffray Urges You to Buy Arena (ARNA, VVUS)",2010-07-16 10:07:00-04:00,VVUS,neutral
1332836.0,Vivus (VVUS) Drops More Than 56% As FDA Rejects Qnexa,2010-07-16 09:34:00-04:00,VVUS,negative
1332837.0,"Benzinga’s Top Pre-Market NASDAQ Losers (VVUS, OREX, PLCM, MAT)",2010-07-16 08:41:00-04:00,VVUS,negative
1332838.0,Vivus (VVUS) Cut To Neutral By JP Morgan,2010-07-16 07:45:00-04:00,VVUS,positive
1332839.0,"Benzinga's After Hours Decliners (GOOG, DF, VVUS)",2010-07-15 18:49:00-04:00,VVUS,neutral
1332840.0,FDA Panel Rejects Vivus Drug (VVUS),2010-07-15 16:37:00-04:00,VVUS,negative
1332841.0,Unemployment Impacting Retail Sales  07-14-2010,2010-07-14 15:03:00-04:00,VVUS,negative
1332842.0,"Benzinga’s Top Upgrades (ENR, CRM, VVUS, AKS)",2010-07-14 11:04:00-04:00,VVUS,positive
1332843.0,SPX Breaks Key 1085 Resistance  07-13-2010,2010-07-13 15:34:00-04:00,VVUS,neutral
1332844.0,"Benzinga’s Volume Movers (ADCT, VVUS, EZCH, ACTG)",2010-07-13 13:06:00-04:00,VVUS,neutral
1332845.0,VVUS Soars Following FDA’s Statement On Qnexa,2010-07-13 09:36:00-04:00,VVUS,neutral
1332846.0,"Benzinga’s Top Pre-Market Gainers (VVUS, OREX, ARNA, CENX)",2010-07-13 08:33:00-04:00,VVUS,positive
1332847.0,Slow Trading - But Stay On Your Toes  07-09-2010,2010-07-09 14:15:00-04:00,VVUS,neutral
1332848.0,Jefferies Concern About Neuropsychiatric Profile Of Qnexa: VVUS,2010-07-08 14:36:00-04:00,VVUS,neutral
1332849.0,Short Vol Position Closed on Vivus (VVUS),2010-07-07 12:03:00-04:00,VVUS,neutral
1332850.0,"Arena And Vivus Receive ‘Hold’ Rating from Jefferies (ARNA, VVUS)",2010-06-28 11:52:00-04:00,VVUS,neutral
1332851.0,Vivus Stock Hinges on FDA Approval of 'Qnexa'; Barron’s (VVUS) ,2010-06-28 09:23:00-04:00,VVUS,positive
1332852.0,Volatility On The Move  06-24-2010,2010-06-24 18:49:00-04:00,VVUS,neutral
1332853.0,Shorts In Control  06-24-2010,2010-06-24 15:57:00-04:00,VVUS,neutral
1332854.0,"Benzinga’s Top Pre-Market Losers (VVUS, ASML, ARMH, QQQQ)",2010-06-18 08:48:00-04:00,VVUS,negative
1332855.0,Risk Appetite Back  06-15-2010,2010-06-15 18:31:00-04:00,VVUS,negative
1332856.0,Jefferies Reiterates Hold Rating on Vivus (VVUS),2010-06-15 10:18:00-04:00,VVUS,neutral
1332857.0,"Benzinga’s Top Pre-Market Losers (CCNE, VVUS, NFLX, NWSA)",2010-06-15 08:41:00-04:00,VVUS,negative
1332858.0,Difference Between an ETF & Index  05-28-2010,2010-06-02 15:28:00-04:00,VVUS,neutral
1332859.0,"Benzinga’s Top Pre-Market Gainers (DIVX, HERO, AMGN, VVUS, JOYG)",2010-06-02 08:51:00-04:00,VVUS,positive
1332860.0,VIVUS Rising On Heavy Volume Today (VVUS) ,2010-05-28 13:46:00-04:00,VVUS,neutral
1332861.0,"Benzinga's After Hours Gainers (VRTX, EXC, VVUS)",2010-05-25 19:03:00-04:00,VVUS,neutral
1332862.0,"Benzinga’s Top Pre-Market Losers (HAUP, GOLD, FSLR, ARMH, VVUS)",2010-05-19 08:45:00-04:00,VVUS,negative
1332863.0,"Benzinga’s Top Pre-Market Gainers (SPRD, LLEN, ALTH, FEED, VVUS)",2010-05-18 09:12:00-04:00,VVUS,positive
1332864.0,"Jim Cramer's Mad Money Lightning Round OT Comments (EK, CGA, VVUS, CELG)",2010-05-05 19:53:00-04:00,VVUS,negative
1332865.0,"Benzinga’s Volume Movers (NTRI, OSTK, EXBD, IVAC, VVUS)",2010-05-04 13:42:00-04:00,VVUS,neutral
1332866.0,"A Look At Bruce Kovner's Portfolio (QCOM, VVUS, FCX, CCL)",2010-05-03 18:50:00-04:00,VVUS,neutral
1332867.0,Brean Initiates Coverage Of Vivus With Buy,2010-04-27 12:10:00-04:00,VVUS,neutral
1332868.0,VIVUS Initiated With Buy,2010-04-14 09:11:00-04:00,VVUS,neutral
1332869.0,"Mike Huckman Is Watching VVUS, ARNA, OREX",2010-04-12 19:32:00-04:00,VVUS,neutral
1332870.0,"Benzinga’s Top Pre-Market Losers (HEAT, LINC, CAGC, VVUS)",2010-03-31 08:24:00-04:00,VVUS,negative
1332871.0,Delta Neutral Trade in Vivus,2010-03-26 10:14:00-04:00,VVUS,neutral
1332872.0,"Benzinga’s News Roundup (RSH, FRO, VVUS, BVF)",2010-03-26 07:57:00-04:00,VVUS,neutral
1332873.0,"Benzinga’s News Roundup (RSH, FRO, VVUS, BVF)",2010-03-26 07:56:00-04:00,VVUS,neutral
1332874.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,VVUS,positive
1332875.0,"Benzinga’s Top Pre-Market Gainers (ITMN, XRTX, SEED, SBLK, VVUS)",2010-03-08 08:13:00-05:00,VVUS,positive
1332876.0,"VIVUS, Inc. (VVUS) Upgraded To Buy",2010-02-04 14:51:00-05:00,VVUS,neutral
1332877.0,Vivus Shares Up 27% Over Three Months,2010-01-21 06:31:00-05:00,VVUS,positive
1332878.0,"Benzinga’s Top Pre-Market Gainers (DDSS, IMMU, VVUS, LUNA, AA, SOLF, TUES)",2010-01-11 08:24:00-05:00,VVUS,positive
1332879.0,"Benzinga’s News Roundup (TAC, BCRX, ASBC, JAH, BP, VVUS)",2010-01-11 08:01:00-05:00,VVUS,neutral
1332880.0,"Benzinga’s Top Pre-Market Gainers (SPIL, BBBY, SONS, SHLD, TRMD, VVUS)",2010-01-07 08:18:00-05:00,VVUS,positive
1332881.0,"Benzinga’s News Roundup (JEF, APPY, VVUS, MS, MSFT, NTRI, UNH)",2009-12-29 09:02:00-05:00,VVUS,neutral
1332882.0,"Benzinga’s Top Pre- Market Gainers (STEC, VVUS, AIG, VICL, OSIS, AMZN, ASML)",2009-12-29 08:12:00-05:00,VVUS,positive
1332883.0,"Benzinga’s Top Pre- Market Gainers (PDLI, NVAX, SIMG, ALTH, SEED, SQNM, VVUS)",2009-11-30 08:37:00-05:00,VVUS,positive
1332884.0,Vivus (VVUS) Reports Encouraging Results Of Erectile Dysfunction Drug Trials,2009-11-19 09:27:00-05:00,VVUS,positive
1332885.0,"Benzinga’s Top Pre- Market Gainers (VVUS, PARD, CSUN, SOLF, NLST, ASMI, CAKE)",2009-11-18 09:08:00-05:00,VVUS,positive
1332886.0,"Jim Cramer Would Stay Away From FUN, POT, VVUS",2009-11-05 14:54:00-05:00,VVUS,positive
1332887.0,Leerink Swann Lowers Price Target On Vivus To $9-$11,2009-11-04 06:37:00-05:00,VVUS,negative
1332888.0,"Pre-Market Movers (CNXT, AXTI, RVSN, VVUS, AIXG)",2009-10-30 09:20:00-04:00,VVUS,neutral
1332889.0,"Vivus Results Support Qnexa's Overall Efficacy and Safety Profile, On Track for NDA Filing By End of 2009",2009-10-29 17:43:00-04:00,VVUS,positive
1332890.0,Vivus Trading Up 15.80% After CEO Appears On CNBC,2009-10-26 10:56:00-04:00,VVUS,neutral
1332891.0,"Today's Morning Top Gainers (CBBO,MDM,BPFH,HEAT,VVUS)",2009-09-18 10:48:00-04:00,VVUS,positive
1332892.0,"AnalystChoice.com Brings You the Best Complimentary Research Report on ERIC, CECO, HLIT, VVUS, CPST and ECLP",2009-08-13 07:39:00-04:00,VVUS,positive
